[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f9jL2IRzmuMXKcCh9EDGHO590Tx5oaUADWM1n6VQkow8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":84,"rows":91},"Alexion Pharmaceuticals, Inc.",[4],252,false,43,60,40367,23,24,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Healthy",47,{"name":18,"count":19},"Paroxysmal Nocturnal Hemoglobinuria",18,{"name":21,"count":22},"Hypophosphatasia",16,{"name":24,"count":25},"Lysosomal Acid Lipase Deficiency",12,{"name":27,"count":28},"Wilson Disease",10,{"name":30,"count":28},"Generalized Myasthenia Gravis",{"name":32,"count":33},"PNH",8,{"name":35,"count":36},"Hypophosphatasia (HPP)",7,[38,43,48,52,57,62,66,71,76,80],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT05778071","Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism","2024-11-15","eneboparatide",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04512235","A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)","2025-04-08","CAEL-101",{"nctId":49,"briefTitle":50,"date":51,"intervention":47},"NCT04504825","A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)","2025-05-10",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT05556096","Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis","2025-05-27","ALXN1720",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT06079281","Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa","2025-07-09","ALXN1850",{"nctId":63,"briefTitle":64,"date":65,"intervention":61},"NCT06079372","Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa","2025-07-23",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT05501717","Safety, PK\u002FPD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants","2025-10-09","ALXN2030",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06291376","Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)","2026-01-05","Ravulizumab",{"nctId":77,"briefTitle":78,"date":79,"intervention":61},"NCT06079359","Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP","2026-01-06",{"nctId":81,"briefTitle":82,"date":83,"intervention":75},"NCT05346354","Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD","2026-03-31",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,429,462,480,715,761,803,825,951,980,1013,1037,1063,1384,1418,1451,1479,1504,1528,1552,1576,1594,1618,1644,1687,1724,1742,1760,1778,1796,1814,1832,1850,1874,1899,1925,1948,1973,1998,2113,2192,2240,2294,2331,2378,2412,2447,2482,2504,2528,2546,2573,2591,2609,2633,2657,2679,2701,2719,2737,2759,2777,2795,2813,2831,2854,2881,2899,2917,2935,2953,2971,2995,3025,3061,3106,3144,3176,3205,3233,3255,3277,3299,3321,3343,3365,3390,3408,3426,3444,3462,3487,3505,3523,3548,3566,3584,3602,3620,3644,3666,3684,3702,3720,3745,3763,3786,3804,3822,3845,3869,3887,3911,3929,3947,3965,3983,4006,4030,4048,4066,4090,4114,4132,4150,4168,4192,4210,4228,4246,4264,4289,4307,4325,4348,4366,4384,4477,4542,4569,4592,4616],{"intervention":75,"totalTrials":93,"cells":94},31,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":111,"PHASE3":136,"PHASE4":377,"NA":406},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[100],{"nctId":101,"briefTitle":102,"status":103,"phases":104,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":109},"NCT05396742","Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers","COMPLETED",[86],"2019-05-21","2018-08-09",49,[15],[75,110],"rHuPH20",{"trials":112,"activeCount":97},[113,126],{"nctId":114,"briefTitle":115,"status":116,"phases":117,"primaryCompletion":118,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":125},"NCT04564339","Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)","TERMINATED",[87],"2025-03-26","2025-08-18","2021-01-19",123,[123,124],"Lupus Nephritis","Immunoglobulin A Nephropathy",[75],{"nctId":127,"briefTitle":128,"status":103,"phases":129,"primaryCompletion":130,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":135},"NCT02605993","Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)",[87],"2017-02-23","2022-01-12","2016-01-04",26,[18,32],[75],{"trials":137,"activeCount":33,"soonestReadout":74},[138,152,162,171,178,191,199,210,221,232,247,258,268,277,288,297,306,316,329,339,349,359,368],{"nctId":139,"briefTitle":140,"status":116,"phases":141,"primaryCompletion":142,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":151},"NCT04369469","Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia",[88],"2021-02-08","2021-04-08","2020-05-10",202,[147,148,149,150],"COVID-19 Severe Pneumonia","Acute Lung Injury","Acute Respiratory Distress Syndrome","Pneumonia, Viral",[75],{"nctId":153,"briefTitle":154,"status":103,"phases":155,"primaryCompletion":156,"completion":55,"start":157,"enrollment":158,"conditions":159,"interventions":161},"NCT04557735","Study of Ravulizumab in Pediatric Participants With HSCT-TMA",[88],"2024-11-26","2020-12-07",41,[160],"Thrombotic Microangiopathy",[75],{"nctId":72,"briefTitle":73,"status":163,"phases":164,"primaryCompletion":74,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":170},"RECRUITING",[88],"2030-07-19","2024-03-29",510,[124,169],"IgAN",[75],{"nctId":81,"briefTitle":82,"status":163,"phases":172,"primaryCompletion":83,"completion":173,"start":174,"enrollment":25,"conditions":175,"interventions":177},[87,88],"2029-04-02","2022-06-23",[176],"Neuromyelitis Optica Spectrum Disorder",[75],{"nctId":179,"briefTitle":180,"status":163,"phases":181,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":190},"NCT06830798","Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation",[88],"2028-02-04","2028-11-06","2025-05-19",450,[187,188,189],"Delayed Graft Function","DGF","Kidney Transplant",[75],{"nctId":192,"briefTitle":193,"status":116,"phases":194,"primaryCompletion":195,"completion":195,"start":196,"enrollment":22,"conditions":197,"interventions":198},"NCT04743804","Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger",[88],"2022-12-22","2021-06-29",[160],[75],{"nctId":200,"briefTitle":201,"status":202,"phases":203,"primaryCompletion":204,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":209},"NCT07557420","Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)","NOT_YET_RECRUITING",[88],"2028-10-31","2026-08-31",21,[208,176],"NMOSD",[75],{"nctId":211,"briefTitle":212,"status":116,"phases":213,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":220},"NCT04248465","An Efficacy and Safety Study of Ravulizumab in ALS Participants",[88],"2021-10-17","2020-03-30",382,[218,219],"Amyotrophic Lateral Sclerosis","ALS",[75],{"nctId":222,"briefTitle":223,"status":103,"phases":224,"primaryCompletion":225,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":230},"NCT03748823","Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab",[88],"2021-02-02","2023-08-31","2019-02-19",139,[18],[231,75],"Ravulizumab OBDS",{"nctId":233,"briefTitle":234,"status":235,"phases":236,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":241,"interventions":246},"NCT05746559","ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE","ACTIVE_NOT_RECRUITING",[88],"2026-05-18","2027-02-17","2023-04-06",736,[242,243,244,245],"Chronic Kidney Disease","CKD","Cardiac Disease","Cardiopulmonary Bypass",[75],{"nctId":248,"briefTitle":249,"status":116,"phases":250,"primaryCompletion":251,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":257},"NCT04999020","Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis",[87,88],"2023-10-26","2024-05-08","2021-11-19",38,[256],"Dermatomyositis",[75],{"nctId":259,"briefTitle":260,"status":103,"phases":261,"primaryCompletion":262,"completion":262,"start":263,"enrollment":145,"conditions":264,"interventions":266},"NCT03056040","ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab",[88],"2022-02-21","2017-05-17",[265],"Paroxysmal Nocturnal Hemoglobinuria (PNH)",[75,267],"Eculizumab",{"nctId":269,"briefTitle":270,"status":103,"phases":271,"primaryCompletion":272,"completion":273,"start":274,"enrollment":19,"conditions":275,"interventions":276},"NCT06578949","Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)",[88],"2025-05-15","2025-12-22","2024-10-10",[18,32],[75],{"nctId":278,"briefTitle":279,"status":103,"phases":280,"primaryCompletion":281,"completion":282,"start":283,"enrollment":284,"conditions":285,"interventions":287},"NCT04201262","An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD",[88],"2022-03-15","2024-10-31","2019-12-09",58,[286,176],"Neuromyelitis Optica",[75],{"nctId":289,"briefTitle":290,"status":103,"phases":291,"primaryCompletion":292,"completion":292,"start":293,"enrollment":284,"conditions":294,"interventions":296},"NCT02949128","Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)",[88],"2023-01-24","2017-01-11",[295],"Atypical Hemolytic Uremic Syndrome (aHUS)",[75],{"nctId":298,"briefTitle":299,"status":103,"phases":300,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":304,"interventions":305},"NCT03131219","Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)",[88],"2022-12-20","2017-08-31",34,[295],[75],{"nctId":307,"briefTitle":308,"status":103,"phases":309,"primaryCompletion":310,"completion":311,"start":312,"enrollment":313,"conditions":314,"interventions":315},"NCT03406507","A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria",[88],"2020-03-25","2022-08-25","2018-02-22",13,[18],[75],{"nctId":317,"briefTitle":318,"status":163,"phases":319,"primaryCompletion":320,"completion":321,"start":322,"enrollment":12,"conditions":323,"interventions":328},"NCT07024563","Study of Ravulizumab in Pediatric Participants With Primary IgAN",[88],"2028-07-12","2029-11-27","2025-06-14",[169,324,124,325,326,327],"IgAVN","Immunoglobulin A Vasculitis Associated Nephritis","Henoch-schonlein Purpura Nephritis","IgA Vasculitis",[75],{"nctId":330,"briefTitle":331,"status":103,"phases":332,"primaryCompletion":333,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":338},"NCT03920293","Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis",[88],"2021-05-11","2023-05-25","2019-03-12",175,[30],[75],{"nctId":340,"briefTitle":341,"status":202,"phases":342,"primaryCompletion":343,"completion":343,"start":344,"enrollment":345,"conditions":346,"interventions":348},"NCT07596784","Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)",[88],"2027-08-27","2026-07-30",20,[30,347],"gMG",[75],{"nctId":350,"briefTitle":351,"status":103,"phases":352,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":357,"interventions":358},"NCT04543591","Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant",[88],"2025-09-19","2026-03-20","2020-12-10",148,[160],[75],{"nctId":360,"briefTitle":361,"status":103,"phases":362,"primaryCompletion":363,"completion":363,"start":364,"enrollment":365,"conditions":366,"interventions":367},"NCT02946463","ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)",[88],"2023-02-28","2016-12-12",272,[265],[75,267],{"nctId":369,"briefTitle":370,"status":235,"phases":371,"primaryCompletion":372,"completion":373,"start":374,"enrollment":25,"conditions":375,"interventions":376},"NCT05644561","Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis",[88],"2026-07-15","2028-06-30","2023-06-24",[30,347],[75],{"trials":378,"activeCount":405,"soonestReadout":399},[379,386,395],{"nctId":380,"briefTitle":381,"status":103,"phases":382,"primaryCompletion":301,"completion":301,"start":383,"enrollment":19,"conditions":384,"interventions":385},"NCT04320602","Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab",[89],"2021-04-14",[18],[267,75],{"nctId":387,"briefTitle":388,"status":163,"phases":389,"primaryCompletion":343,"completion":343,"start":390,"enrollment":391,"conditions":392,"interventions":393},"NCT07221838","A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab",[89],"2026-03-04",75,[30,347],[75,394],"Prednisone\u002FPrednisolone",{"nctId":396,"briefTitle":397,"status":163,"phases":398,"primaryCompletion":399,"completion":399,"start":400,"enrollment":345,"conditions":401,"interventions":404},"NCT07308574","Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS",[89],"2027-06-25","2025-12-19",[402,403],"aHUS","Atypical Hemolytic Uremic Syndrome",[75],2,{"trials":407,"activeCount":428,"soonestReadout":412},[408,418],{"nctId":409,"briefTitle":410,"status":163,"phases":411,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":415,"interventions":417},"NCT06967480","Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis",[],"2027-06-30","2025-07-31",40,[30,416],"Anti-AChR Antibody Positive",[75],{"nctId":419,"briefTitle":420,"status":103,"phases":421,"primaryCompletion":422,"completion":423,"start":424,"enrollment":425,"conditions":426,"interventions":427},"NCT05274633","Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria",[],"2024-06-30","2025-03-24","2022-06-17",120,[18],[75],1,{"intervention":430,"totalTrials":405,"cells":431},"Acoramidis",{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":444,"PHASE3":446,"PHASE4":448,"NA":460},{"trials":433,"activeCount":97},[],{"trials":435,"activeCount":97},[436],{"nctId":437,"briefTitle":438,"status":103,"phases":439,"primaryCompletion":440,"completion":440,"start":441,"enrollment":19,"conditions":442,"interventions":443},"NCT04958135","Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants",[86],"2021-08-04","2021-05-30",[15],[430],{"trials":445,"activeCount":97},[],{"trials":447,"activeCount":97},[],{"trials":449,"activeCount":428,"soonestReadout":454},[450],{"nctId":451,"briefTitle":452,"status":163,"phases":453,"primaryCompletion":454,"completion":454,"start":455,"enrollment":456,"conditions":457,"interventions":459},"NCT07306949","Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers",[89],"2028-03-31","2025-10-01",200,[458],"Transthyretin-type Cardiac Amyloidosis",[430],{"trials":461,"activeCount":97},[],{"intervention":394,"totalTrials":428,"cells":463},{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":468,"PHASE3":470,"PHASE4":472,"NA":478},{"trials":465,"activeCount":97},[],{"trials":467,"activeCount":97},[],{"trials":469,"activeCount":97},[],{"trials":471,"activeCount":97},[],{"trials":473,"activeCount":428,"soonestReadout":343},[474],{"nctId":387,"briefTitle":388,"status":163,"phases":475,"primaryCompletion":343,"completion":343,"start":390,"enrollment":391,"conditions":476,"interventions":477},[89],[30,347],[75,394],{"trials":479,"activeCount":97},[],{"intervention":481,"totalTrials":482,"cells":483},"Danicopan",22,{"EARLY_PHASE1":484,"PHASE1":486,"PHASE2":591,"PHASE3":655,"PHASE4":687,"NA":689},{"trials":485,"activeCount":97},[],{"trials":487,"activeCount":97},[488,497,510,519,528,538,547,560,568,582],{"nctId":489,"briefTitle":490,"status":103,"phases":491,"primaryCompletion":492,"completion":492,"start":493,"enrollment":22,"conditions":494,"interventions":496},"NCT04935294","Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction",[86],"2018-05-29","2018-01-24",[15,495],"Renal Dysfunction",[481],{"nctId":498,"briefTitle":499,"status":103,"phases":500,"primaryCompletion":501,"completion":502,"start":503,"enrollment":504,"conditions":505,"interventions":506},"NCT04709094","A Drug Interaction Study of Danicopan",[86],"2019-10-14","2020-04-17","2019-07-28",52,[15],[481,507,508,509],"Warfarin","Bupropion","Ethinyl Estradiol\u002FNorethindrone",{"nctId":511,"briefTitle":512,"status":103,"phases":513,"primaryCompletion":514,"completion":514,"start":515,"enrollment":516,"conditions":517,"interventions":518},"NCT04551599","A Study of the Effects of Food and Age on Danicopan",[86],"2021-02-03","2020-02-21",27,[15],[481],{"nctId":520,"briefTitle":521,"status":103,"phases":522,"primaryCompletion":523,"completion":523,"start":524,"enrollment":525,"conditions":526,"interventions":527},"NCT04451434","Study of Danicopan in Participants of Japanese Descent",[86],"2020-09-28","2020-08-17",9,[15],[481],{"nctId":529,"briefTitle":530,"status":103,"phases":531,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":535,"interventions":536},"NCT05016206","A Study of the Cardiac Effects of Danicopan in Healthy Adults",[86],"2018-10-12","2018-07-26",33,[15],[481,537],"Moxifloxacin",{"nctId":539,"briefTitle":540,"status":103,"phases":541,"primaryCompletion":542,"completion":542,"start":543,"enrollment":544,"conditions":545,"interventions":546},"NCT04889677","Study of a Single Dose of Danicopan in Healthy Participants",[86],"2016-06-21","2016-02-04",44,[15],[481],{"nctId":548,"briefTitle":549,"status":103,"phases":550,"primaryCompletion":551,"completion":552,"start":553,"enrollment":554,"conditions":555,"interventions":556},"NCT03108274","A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants",[86],"2017-06-02","2017-06-16","2017-04-18",35,[15],[481,557,558,559],"Midazolam","Fexofenadine","Mycophenolate Mofetil",{"nctId":561,"briefTitle":562,"status":103,"phases":563,"primaryCompletion":293,"completion":293,"start":564,"enrollment":565,"conditions":566,"interventions":567},"NCT04889690","Study of Multiple Doses of Danicopan in Healthy Participants",[86],"2016-05-21",45,[15],[481],{"nctId":569,"briefTitle":570,"status":103,"phases":571,"primaryCompletion":572,"completion":572,"start":573,"enrollment":574,"conditions":575,"interventions":576},"NCT05109390","A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults",[86],"2018-10-17","2018-07-27",72,[15],[481,577,578,579,580,581],"Cyclosporine","Tacrolimus","Calcium Carbonate","Aluminum\u002FMagnesium Hydroxide\u002FSimethicone","Omeprazole",{"nctId":583,"briefTitle":584,"status":103,"phases":585,"primaryCompletion":586,"completion":586,"start":587,"enrollment":22,"conditions":588,"interventions":590},"NCT03555539","Study of Danicopan in Participants With Hepatic Impairment",[86],"2018-09-21","2018-05-01",[589],"Hepatic Impairment",[481],{"trials":592,"activeCount":97},[593,604,619,628,638,647],{"nctId":594,"briefTitle":595,"status":116,"phases":596,"primaryCompletion":597,"completion":598,"start":599,"enrollment":600,"conditions":601,"interventions":603},"NCT05019521","A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration",[87],"2024-07-05","2025-01-21","2021-08-23",365,[602],"Geographic Atrophy",[481],{"nctId":605,"briefTitle":606,"status":103,"phases":607,"primaryCompletion":608,"completion":609,"start":610,"enrollment":611,"conditions":612,"interventions":618},"NCT03124368","A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN",[87],"2018-12-21","2019-01-09","2017-08-09",6,[613,614,615,616,617],"C3 Glomerulonephritis","Dense Deposit Disease","C3 Glomerulopathy","Immune Complex Mediated Membranoproliferative Glomerulonephritis","Membranoproliferative Glomerulonephritis Types I, II, and III",[481],{"nctId":620,"briefTitle":621,"status":103,"phases":622,"primaryCompletion":623,"completion":624,"start":625,"enrollment":25,"conditions":626,"interventions":627},"NCT03472885","Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab",[87],"2019-09-20","2023-01-05","2018-05-08",[265],[481,267],{"nctId":629,"briefTitle":630,"status":116,"phases":631,"primaryCompletion":632,"completion":632,"start":633,"enrollment":482,"conditions":634,"interventions":637},"NCT03459443","A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471",[87],"2021-03-29","2018-06-20",[613,615,635,636,614],"Immune Complex Membranoproliferative Glomerulonephritis","IC-MPGN",[481],{"nctId":639,"briefTitle":640,"status":103,"phases":641,"primaryCompletion":642,"completion":643,"start":644,"enrollment":313,"conditions":645,"interventions":646},"NCT03369236","A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)",[87],"2019-12-11","2020-12-18","2018-06-12",[615,613,614],[481],{"nctId":648,"briefTitle":649,"status":103,"phases":650,"primaryCompletion":651,"completion":651,"start":652,"enrollment":28,"conditions":653,"interventions":654},"NCT03053102","Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)",[87],"2018-11-14","2017-03-31",[265],[481],{"trials":656,"activeCount":405,"soonestReadout":672},[657,668,677],{"nctId":658,"briefTitle":659,"status":103,"phases":660,"primaryCompletion":661,"completion":662,"start":663,"enrollment":664,"conditions":665,"interventions":666},"NCT04469465","Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)",[88],"2022-06-29","2024-01-16","2020-12-16",86,[18],[481,667],"C5 Inhibitor",{"nctId":669,"briefTitle":670,"status":235,"phases":671,"primaryCompletion":672,"completion":672,"start":673,"enrollment":674,"conditions":675,"interventions":676},"NCT05389449","A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH",[88],"2026-07-31","2022-10-28",80,[18],[481],{"nctId":678,"briefTitle":679,"status":163,"phases":680,"primaryCompletion":681,"completion":682,"start":683,"enrollment":611,"conditions":684,"interventions":686},"NCT06449001","Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis",[88],"2027-05-28","2028-03-10","2025-08-11",[18,32,685],"Extravascular Hemolysis",[481],{"trials":688,"activeCount":97},[],{"trials":690,"activeCount":405,"soonestReadout":712},[691,701,708],{"nctId":692,"briefTitle":693,"status":235,"phases":694,"primaryCompletion":695,"completion":695,"start":696,"enrollment":697,"conditions":698,"interventions":699},"NCT07413250","Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data",[],"2030-01-15","2026-01-14",50,[18,32],[481,700],"Soliris\u002FUltomiris",{"nctId":702,"briefTitle":703,"status":704,"phases":705,"conditions":706,"interventions":707},"NCT05982938","Danicopan Early Access Program","AVAILABLE",[],[18,32,685],[481],{"nctId":709,"briefTitle":710,"status":235,"phases":711,"primaryCompletion":712,"completion":712,"start":119,"enrollment":697,"conditions":713,"interventions":714},"NCT07413679","Long-term Safety of Danicopan: IPIG Registry-based Cohort Study",[],"2029-07-01",[18,32],[481],{"intervention":61,"totalTrials":716,"cells":717},4,{"EARLY_PHASE1":718,"PHASE1":720,"PHASE2":731,"PHASE3":733,"PHASE4":757,"NA":759},{"trials":719,"activeCount":97},[],{"trials":721,"activeCount":97},[722],{"nctId":723,"briefTitle":724,"status":103,"phases":725,"primaryCompletion":726,"completion":726,"start":727,"enrollment":728,"conditions":729,"interventions":730},"NCT04980248","Study of ALXN1850 in Participants With Hypophosphatasia (HPP)",[86],"2022-08-24","2021-09-28",15,[21],[61],{"trials":732,"activeCount":97},[],{"trials":734,"activeCount":756,"soonestReadout":60},[735,742,749],{"nctId":77,"briefTitle":78,"status":235,"phases":736,"primaryCompletion":79,"completion":737,"start":738,"enrollment":739,"conditions":740,"interventions":741},[88],"2028-08-24","2024-05-14",30,[21],[61],{"nctId":63,"briefTitle":64,"status":235,"phases":743,"primaryCompletion":65,"completion":744,"start":745,"enrollment":8,"conditions":746,"interventions":747},[88],"2028-02-29","2024-04-02",[21],[61,748],"asfotase alfa",{"nctId":58,"briefTitle":59,"status":235,"phases":750,"primaryCompletion":60,"completion":751,"start":752,"enrollment":753,"conditions":754,"interventions":755},[88],"2028-03-29","2024-01-03",124,[21],[61],3,{"trials":758,"activeCount":97},[],{"trials":760,"activeCount":97},[],{"intervention":47,"totalTrials":756,"cells":762},{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":767,"PHASE3":781,"PHASE4":799,"NA":801},{"trials":764,"activeCount":97},[],{"trials":766,"activeCount":97},[],{"trials":768,"activeCount":97},[769],{"nctId":770,"briefTitle":771,"status":103,"phases":772,"primaryCompletion":773,"completion":773,"start":774,"enrollment":775,"conditions":776,"interventions":778},"NCT04304144","A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis",[87],"2023-11-14","2020-03-18",25,[777],"AL Amyloidosis",[47,779,780],"SoC: cyclophosphamide, bortezomib, and Dexamethasone","Daratumumab",{"trials":782,"activeCount":405,"soonestReadout":46},[783,791],{"nctId":49,"briefTitle":50,"status":235,"phases":784,"primaryCompletion":51,"completion":785,"start":786,"enrollment":787,"conditions":788,"interventions":789},[88],"2027-10-22","2020-08-25",125,[777],[47,790],"cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen",{"nctId":44,"briefTitle":45,"status":235,"phases":792,"primaryCompletion":46,"completion":793,"start":794,"enrollment":795,"conditions":796,"interventions":797},[88],"2027-04-08","2020-11-03",281,[777],[47,798],"cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen",{"trials":800,"activeCount":97},[],{"trials":802,"activeCount":97},[],{"intervention":790,"totalTrials":405,"cells":804},{"EARLY_PHASE1":805,"PHASE1":807,"PHASE2":809,"PHASE3":811,"PHASE4":821,"NA":823},{"trials":806,"activeCount":97},[],{"trials":808,"activeCount":97},[],{"trials":810,"activeCount":97},[],{"trials":812,"activeCount":405,"soonestReadout":46},[813,817],{"nctId":49,"briefTitle":50,"status":235,"phases":814,"primaryCompletion":51,"completion":785,"start":786,"enrollment":787,"conditions":815,"interventions":816},[88],[777],[47,790],{"nctId":44,"briefTitle":45,"status":235,"phases":818,"primaryCompletion":46,"completion":793,"start":794,"enrollment":795,"conditions":819,"interventions":820},[88],[777],[47,798],{"trials":822,"activeCount":97},[],{"trials":824,"activeCount":97},[],{"intervention":748,"totalTrials":826,"cells":827},14,{"EARLY_PHASE1":828,"PHASE1":830,"PHASE2":842,"PHASE3":894,"PHASE4":908,"NA":927},{"trials":829,"activeCount":97},[],{"trials":831,"activeCount":97},[832],{"nctId":833,"briefTitle":834,"status":103,"phases":835,"primaryCompletion":836,"completion":837,"start":838,"enrollment":611,"conditions":839,"interventions":840},"NCT00739505","Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)",[86],"2009-01","2009-02","2008-08",[35],[841,841],"Asfotase Alfa",{"trials":843,"activeCount":97},[844,853,862,870,879,886],{"nctId":845,"briefTitle":846,"status":103,"phases":847,"primaryCompletion":848,"completion":848,"start":849,"enrollment":850,"conditions":851,"interventions":852},"NCT01163149","Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)",[87],"2016-06","2010-06",19,[21],[748,748],{"nctId":854,"briefTitle":855,"status":103,"phases":856,"primaryCompletion":857,"completion":857,"start":858,"enrollment":859,"conditions":860,"interventions":861},"NCT00744042","Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)",[86,87],"2010-05","2008-09",11,[35],[748],{"nctId":863,"briefTitle":864,"status":103,"phases":865,"primaryCompletion":866,"completion":866,"start":867,"enrollment":313,"conditions":868,"interventions":869},"NCT00952484","Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)",[87],"2010-07","2009-09",[35],[748,748],{"nctId":871,"briefTitle":872,"status":103,"phases":873,"primaryCompletion":874,"completion":874,"start":875,"enrollment":516,"conditions":876,"interventions":877},"NCT02797821","Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)",[87],"2017-06-21","2016-06-06",[21],[878],"Asfotase alfa",{"nctId":880,"briefTitle":881,"status":103,"phases":882,"primaryCompletion":848,"completion":848,"start":883,"enrollment":25,"conditions":884,"interventions":885},"NCT01203826","Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP)",[87],"2010-04",[35],[841],{"nctId":887,"briefTitle":888,"status":103,"phases":889,"primaryCompletion":890,"completion":890,"start":891,"enrollment":28,"conditions":892,"interventions":893},"NCT01205152","Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)",[87],"2016-08","2009-04",[21],[748],{"trials":895,"activeCount":428,"soonestReadout":65},[896,904],{"nctId":897,"briefTitle":898,"status":103,"phases":899,"primaryCompletion":900,"completion":900,"start":866,"enrollment":901,"conditions":902,"interventions":903},"NCT01176266","Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)",[87,88],"2016-09",69,[21],[748],{"nctId":63,"briefTitle":64,"status":235,"phases":905,"primaryCompletion":65,"completion":744,"start":745,"enrollment":8,"conditions":906,"interventions":907},[88],[21],[61,748],{"trials":909,"activeCount":97},[910,919],{"nctId":911,"briefTitle":912,"status":913,"phases":914,"primaryCompletion":915,"completion":915,"start":916,"enrollment":97,"conditions":917,"interventions":918},"NCT04189315","Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease","WITHDRAWN",[89],"2022-08","2020-04",[21],[748],{"nctId":920,"briefTitle":921,"status":103,"phases":922,"primaryCompletion":923,"completion":923,"start":924,"enrollment":313,"conditions":925,"interventions":926},"NCT02531867","Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan",[89],"2015-11","2015-06",[21],[841],{"trials":928,"activeCount":428,"soonestReadout":948},[929,936,944],{"nctId":930,"briefTitle":931,"status":932,"phases":933,"conditions":934,"interventions":935},"NCT02496689","Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)","APPROVED_FOR_MARKETING",[],[21],[748],{"nctId":937,"briefTitle":938,"status":103,"phases":939,"primaryCompletion":940,"completion":940,"start":941,"enrollment":697,"conditions":942,"interventions":943},"NCT04195763","Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)",[],"2024-04-12","2019-11-06",[21],[748],{"nctId":945,"briefTitle":946,"status":163,"phases":947,"primaryCompletion":948,"completion":948,"start":311,"enrollment":739,"conditions":949,"interventions":950},"NCT05234567","A Prospective Sub-Study of the Global Hypophosphatasia Registry",[],"2028-07-18",[21],[841],{"intervention":56,"totalTrials":405,"cells":952},{"EARLY_PHASE1":953,"PHASE1":955,"PHASE2":965,"PHASE3":967,"PHASE4":976,"NA":978},{"trials":954,"activeCount":97},[],{"trials":956,"activeCount":97},[957],{"nctId":958,"briefTitle":959,"status":103,"phases":960,"primaryCompletion":961,"completion":961,"start":661,"enrollment":313,"conditions":962,"interventions":964},"NCT05314231","Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria",[86],"2023-05-31",[963],"Proteinuria",[56],{"trials":966,"activeCount":97},[],{"trials":968,"activeCount":428,"soonestReadout":55},[969],{"nctId":53,"briefTitle":54,"status":235,"phases":970,"primaryCompletion":55,"completion":971,"start":972,"enrollment":973,"conditions":974,"interventions":975},[88],"2027-08-31","2022-11-21",261,[30],[56],{"trials":977,"activeCount":97},[],{"trials":979,"activeCount":97},[],{"intervention":981,"totalTrials":405,"cells":982},"Gefurulimab",{"EARLY_PHASE1":983,"PHASE1":985,"PHASE2":996,"PHASE3":998,"PHASE4":1009,"NA":1011},{"trials":984,"activeCount":97},[],{"trials":986,"activeCount":97},[987],{"nctId":988,"briefTitle":989,"status":103,"phases":990,"primaryCompletion":991,"completion":991,"start":992,"enrollment":33,"conditions":993,"interventions":994},"NCT06677138","PK Study of Gefurulimab SC in Healthy Chinese Adult Participants",[86],"2025-03-19","2024-10-28",[15],[995],"gefurulimab",{"trials":997,"activeCount":97},[],{"trials":999,"activeCount":428,"soonestReadout":1004},[1000],{"nctId":1001,"briefTitle":1002,"status":163,"phases":1003,"primaryCompletion":1004,"completion":1005,"start":1006,"enrollment":25,"conditions":1007,"interventions":1008},"NCT06607627","PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis",[88],"2026-12-15","2029-01-23","2024-11-13",[30,347],[981],{"trials":1010,"activeCount":97},[],{"trials":1012,"activeCount":97},[],{"intervention":42,"totalTrials":428,"cells":1014},{"EARLY_PHASE1":1015,"PHASE1":1017,"PHASE2":1019,"PHASE3":1021,"PHASE4":1033,"NA":1035},{"trials":1016,"activeCount":97},[],{"trials":1018,"activeCount":97},[],{"trials":1020,"activeCount":97},[],{"trials":1022,"activeCount":428,"soonestReadout":41},[1023],{"nctId":39,"briefTitle":40,"status":235,"phases":1024,"primaryCompletion":41,"completion":1025,"start":1026,"enrollment":1027,"conditions":1028,"interventions":1032},[88],"2027-06-16","2023-06-07",165,[1029,1030,1031],"Chronic Hypoparathyroidism","Endocrine System Diseases","Parathyroid Diseases",[42],{"trials":1034,"activeCount":97},[],{"trials":1036,"activeCount":97},[],{"intervention":1038,"totalTrials":428,"cells":1039},"ALXN2220",{"EARLY_PHASE1":1040,"PHASE1":1042,"PHASE2":1044,"PHASE3":1046,"PHASE4":1059,"NA":1061},{"trials":1041,"activeCount":97},[],{"trials":1043,"activeCount":97},[],{"trials":1045,"activeCount":97},[],{"trials":1047,"activeCount":428,"soonestReadout":1052},[1048],{"nctId":1049,"briefTitle":1050,"status":235,"phases":1051,"primaryCompletion":1052,"completion":1053,"start":1054,"enrollment":1055,"conditions":1056,"interventions":1058},"NCT06183931","Study of ALXN2220 Versus Placebo in Adults With ATTR-CM",[88],"2027-06-07","2027-10-05","2024-01-11",1181,[1057],"Transthyretin Amyloid Cardiomyopathy",[1038],{"trials":1060,"activeCount":97},[],{"trials":1062,"activeCount":97},[],{"intervention":267,"totalTrials":1064,"cells":1065},37,{"EARLY_PHASE1":1066,"PHASE1":1068,"PHASE2":1070,"PHASE3":1190,"PHASE4":1346,"NA":1360},{"trials":1067,"activeCount":97},[],{"trials":1069,"activeCount":97},[],{"trials":1071,"activeCount":97},[1072,1081,1092,1101,1105,1114,1124,1133,1139,1147,1158,1167,1175,1181],{"nctId":1073,"briefTitle":1074,"status":103,"phases":1075,"primaryCompletion":1076,"completion":1077,"start":866,"enrollment":544,"conditions":1078,"interventions":1080},"NCT01194973","An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome",[87],"2013-10","2014-02",[1079],"Atypical Hemolytic-Uremic Syndrome",[267],{"nctId":1082,"briefTitle":1083,"status":103,"phases":1084,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":1088,"conditions":1089,"interventions":1090},"NCT00844428","Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS",[87],"2010-10","2013-12","2009-07",5,[403],[1091],"eculizumab",{"nctId":1093,"briefTitle":1094,"status":103,"phases":1095,"primaryCompletion":858,"completion":1096,"start":1097,"enrollment":206,"conditions":1098,"interventions":1100},"NCT00485576","Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma",[87],"2008-11","2007-09",[1099],"Allergic Asthma",[1091],{"nctId":620,"briefTitle":621,"status":103,"phases":1102,"primaryCompletion":623,"completion":624,"start":625,"enrollment":25,"conditions":1103,"interventions":1104},[87],[265],[481,267],{"nctId":1106,"briefTitle":1107,"status":103,"phases":1108,"primaryCompletion":1109,"completion":1110,"start":1111,"enrollment":428,"conditions":1112,"interventions":1113},"NCT00844844","Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS",[87],"2010-09","2013-07","2009-05",[403],[267],{"nctId":1115,"briefTitle":1116,"status":103,"phases":1117,"primaryCompletion":1118,"completion":1119,"start":1120,"enrollment":674,"conditions":1121,"interventions":1123},"NCT01567085","Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor",[87],"2015-06-11","2017-05-24","2012-08-29",[1122],"Stage V Chronic Kidney Disease",[267],{"nctId":1125,"briefTitle":1126,"status":103,"phases":1127,"primaryCompletion":1128,"completion":1128,"start":1129,"enrollment":1130,"conditions":1131,"interventions":1132},"NCT01192399","Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients",[87],"2008-06","2007-11",29,[18],[267],{"nctId":1134,"briefTitle":1135,"status":103,"phases":1136,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":728,"conditions":1137,"interventions":1138},"NCT00838513","Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)",[87],[403],[1091],{"nctId":1140,"briefTitle":1141,"status":103,"phases":1142,"primaryCompletion":1109,"completion":1143,"start":1144,"enrollment":516,"conditions":1145,"interventions":1146},"NCT01194804","E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients",[87],"2011-03","2008-04",[18],[267],{"nctId":1148,"briefTitle":1149,"status":116,"phases":1150,"primaryCompletion":1151,"completion":1152,"start":1153,"enrollment":1154,"conditions":1155,"interventions":1157},"NCT01399593","Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization",[87],"2014-05-13","2015-11-13","2011-11-02",102,[1156],"Antibody Mediated Rejection",[267],{"nctId":1159,"briefTitle":1160,"status":103,"phases":1161,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":405,"conditions":1165,"interventions":1166},"NCT01757431","The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)",[87],"2013-09-24","2013-09-25","2012-05-16",[295],[267],{"nctId":1168,"briefTitle":1169,"status":103,"phases":1170,"primaryCompletion":1171,"completion":1172,"start":1109,"enrollment":482,"conditions":1173,"interventions":1174},"NCT01193348","An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome",[87],"2014-01","2014-04",[1079],[267],{"nctId":1176,"briefTitle":1177,"status":103,"phases":1178,"primaryCompletion":1109,"completion":1110,"start":1111,"enrollment":22,"conditions":1179,"interventions":1180},"NCT00844545","Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS",[87],[403],[267],{"nctId":1182,"briefTitle":1183,"status":116,"phases":1184,"primaryCompletion":1143,"completion":1185,"start":1186,"enrollment":826,"conditions":1187,"interventions":1189},"NCT00727194","Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis",[87],"2011-07","2008-10",[1188],"Myasthenia Gravis",[1091],{"trials":1191,"activeCount":428,"soonestReadout":1242},[1192,1201,1210,1219,1229,1238,1247,1255,1265,1275,1285,1293,1297,1308,1316,1325,1332,1342],{"nctId":1193,"briefTitle":1194,"status":103,"phases":1195,"primaryCompletion":1196,"completion":1196,"start":1197,"enrollment":1198,"conditions":1199,"interventions":1200},"NCT02003144","An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients",[88],"2021-07-12","2015-01-12",119,[286,176],[1091],{"nctId":1202,"briefTitle":1203,"status":103,"phases":1204,"primaryCompletion":1205,"completion":1205,"start":1206,"enrollment":775,"conditions":1207,"interventions":1209},"NCT05876351","Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China",[88],"2025-05-07","2023-07-14",[1208],"Atypical Hemolytic Uremic",[267],{"nctId":1211,"briefTitle":1212,"status":116,"phases":1213,"primaryCompletion":1214,"completion":1214,"start":1215,"enrollment":1216,"conditions":1217,"interventions":1218},"NCT01892345","A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)",[88],"2018-07-17","2014-04-11",143,[286,176],[267],{"nctId":1220,"briefTitle":1221,"status":103,"phases":1222,"completion":1223,"start":1224,"enrollment":1225,"conditions":1226,"interventions":1228},"NCT00122304","Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab",[88],"2006-11","2004-12",85,[1227],"Hemoglobinuria, Paroxysmal",[1091],{"nctId":1230,"briefTitle":1231,"status":103,"phases":1232,"primaryCompletion":1233,"completion":1233,"start":1234,"enrollment":1235,"conditions":1236,"interventions":1237},"NCT02145182","Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)",[87,88],"2016-11-22","2014-08-21",288,[187],[267],{"nctId":1239,"briefTitle":1240,"status":235,"phases":1241,"primaryCompletion":1242,"completion":1242,"start":1243,"enrollment":206,"conditions":1244,"interventions":1246},"NCT06724809","Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD",[88],"2026-12-07","2025-01-16",[208,1245],"Neuromyelitis Optica Spectrum Disorders",[1091],{"nctId":1248,"briefTitle":1249,"status":103,"phases":1250,"primaryCompletion":1251,"completion":1251,"start":1252,"enrollment":775,"conditions":1253,"interventions":1254},"NCT05886244","Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China",[88],"2025-04-14","2023-07-05",[18],[267],{"nctId":1256,"briefTitle":1257,"status":103,"phases":1258,"primaryCompletion":1259,"completion":1260,"start":1185,"enrollment":1261,"conditions":1262,"interventions":1264},"NCT01410916","Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)",[87,88],"2012-01","2012-06",198,[1263],"Shiga-like Toxin-producing Escherichia Coli",[267],{"nctId":1266,"briefTitle":1267,"status":103,"phases":1268,"primaryCompletion":1269,"completion":1269,"start":1270,"enrollment":1271,"conditions":1272,"interventions":1274},"NCT04752566","A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome",[88],"2022-08-03","2021-03-08",57,[1273],"Guillain-Barre Syndrome",[267],{"nctId":1276,"briefTitle":1277,"status":103,"phases":1278,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":1282,"interventions":1284},"NCT02301624","Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis",[88],"2019-01-15","2014-11-12",117,[1283],"Refractory Generalized Myasthenia Gravis",[267],{"nctId":1286,"briefTitle":1287,"status":116,"phases":1288,"primaryCompletion":1289,"completion":1289,"start":1290,"enrollment":1088,"conditions":1291,"interventions":1292},"NCT04155424","A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder",[87,88],"2023-07-31","2020-01-14",[286,176],[267],{"nctId":259,"briefTitle":260,"status":103,"phases":1294,"primaryCompletion":262,"completion":262,"start":263,"enrollment":145,"conditions":1295,"interventions":1296},[88],[265],[75,267],{"nctId":1298,"briefTitle":1299,"status":103,"phases":1300,"primaryCompletion":1301,"completion":1302,"start":1303,"enrollment":25,"conditions":1304,"interventions":1307},"NCT03759366","A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)",[88],"2022-01-06","2023-11-06","2018-12-28",[1188,1305,1306],"Myasthenia Gravis, Juvenile Form","Myasthenia Gravis, Generalized",[267],{"nctId":1309,"briefTitle":1310,"status":103,"phases":1311,"completion":1312,"start":1313,"enrollment":391,"conditions":1314,"interventions":1315},"NCT00122330","Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients",[88],"2006-01","2004-10",[1227],[1091],{"nctId":1317,"briefTitle":1318,"status":103,"phases":1319,"primaryCompletion":858,"completion":1186,"start":1320,"enrollment":1321,"conditions":1322,"interventions":1324},"NCT00122317","Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)",[88],"2005-05",187,[1323],"Paroxysmal Hemoglobinuria, Nocturnal",[1091],{"nctId":1326,"briefTitle":1327,"status":103,"phases":1328,"primaryCompletion":1329,"completion":848,"start":1086,"enrollment":787,"conditions":1330,"interventions":1331},"NCT01997229","Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)",[88],"2016-02",[1283],[267],{"nctId":1333,"briefTitle":1334,"status":103,"phases":1335,"primaryCompletion":1336,"completion":1336,"start":1337,"enrollment":728,"conditions":1338,"interventions":1341},"NCT06764160","Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG",[88],"2025-12-29","2025-01-06",[1339,1340],"Generalized Myasthenia Gravis (gMG)","Refractory gMG",[267],{"nctId":360,"briefTitle":361,"status":103,"phases":1343,"primaryCompletion":363,"completion":363,"start":364,"enrollment":365,"conditions":1344,"interventions":1345},[88],[265],[75,267],{"trials":1347,"activeCount":97},[1348,1352],{"nctId":380,"briefTitle":381,"status":103,"phases":1349,"primaryCompletion":301,"completion":301,"start":383,"enrollment":19,"conditions":1350,"interventions":1351},[89],[18],[267,75],{"nctId":1353,"briefTitle":1354,"status":103,"phases":1355,"primaryCompletion":1356,"completion":1356,"start":1357,"enrollment":36,"conditions":1358,"interventions":1359},"NCT00867932","Eculizumab Pharmacokinetics\u002FPharmacodynamics Study in Pediatric\u002FAdolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)",[89],"2011-05-12","2009-10-02",[1227],[267],{"trials":1361,"activeCount":97},[1362,1370,1378],{"nctId":1363,"briefTitle":1364,"status":1365,"phases":1366,"conditions":1367,"interventions":1369},"NCT04802083","COVID-19 Soliris Expanded Access Protocol","NO_LONGER_AVAILABLE",[],[1368],"Covid19",[267],{"nctId":1371,"briefTitle":1372,"status":1365,"phases":1373,"conditions":1374,"interventions":1377},"NCT04355494","SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19",[],[1375,150,1376],"COVID-19","Acute Lung Injury\u002FAcute Respiratory Distress Syndrome (ARDS)",[1091],{"nctId":1379,"briefTitle":1380,"status":932,"phases":1381,"conditions":1382,"interventions":1383},"NCT00438789","The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol",[],[1227],[1091],{"intervention":70,"totalTrials":405,"cells":1385},{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1397,"PHASE3":1412,"PHASE4":1414,"NA":1416},{"trials":1387,"activeCount":97},[],{"trials":1389,"activeCount":428,"soonestReadout":69},[1390],{"nctId":67,"briefTitle":68,"status":235,"phases":1391,"primaryCompletion":69,"completion":1392,"start":1393,"enrollment":1394,"conditions":1395,"interventions":1396},[86],"2026-10-14","2022-08-16",48,[15],[70],{"trials":1398,"activeCount":428,"soonestReadout":1403},[1399],{"nctId":1400,"briefTitle":1401,"status":163,"phases":1402,"primaryCompletion":1403,"completion":1404,"start":1405,"enrollment":565,"conditions":1406,"interventions":1411},"NCT06744647","Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation",[87],"2027-10-11","2028-11-07","2025-03-07",[1407,1408,1409,1410],"Antibody-Mediated Rejection","Kidney Transplantation","Biopsy-proven Histologic Scores","AMR",[70],{"trials":1413,"activeCount":97},[],{"trials":1415,"activeCount":97},[],{"trials":1417,"activeCount":97},[],{"intervention":1419,"totalTrials":405,"cells":1420},"ALXN1920",{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1434,"PHASE3":1445,"PHASE4":1447,"NA":1449},{"trials":1422,"activeCount":97},[],{"trials":1424,"activeCount":97},[1425],{"nctId":1426,"briefTitle":1427,"status":103,"phases":1428,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":1394,"conditions":1431,"interventions":1433},"NCT05751642","Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants",[86],"2023-12-04","2023-04-19",[1432],"Healthy Participants",[1419,1419,1419],{"trials":1435,"activeCount":428,"soonestReadout":1440},[1436],{"nctId":1437,"briefTitle":1438,"status":163,"phases":1439,"primaryCompletion":1440,"completion":1441,"start":353,"enrollment":739,"conditions":1442,"interventions":1444},"NCT07157787","Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)",[87],"2027-07-02","2027-07-09",[1443],"Primary Membranous Nephropathy",[1419],{"trials":1446,"activeCount":97},[],{"trials":1448,"activeCount":97},[],{"trials":1450,"activeCount":97},[],{"intervention":1452,"totalTrials":428,"cells":1453},"AZD0120",{"EARLY_PHASE1":1454,"PHASE1":1456,"PHASE2":1458,"PHASE3":1473,"PHASE4":1475,"NA":1477},{"trials":1455,"activeCount":97},[],{"trials":1457,"activeCount":97},[],{"trials":1459,"activeCount":428,"soonestReadout":1464},[1460],{"nctId":1461,"briefTitle":1462,"status":163,"phases":1463,"primaryCompletion":1464,"completion":1465,"start":119,"enrollment":1466,"conditions":1467,"interventions":1472},"NCT07081646","A Phase 1b\u002F2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.",[86,87],"2029-08-15","2031-02-14",91,[1468,1469,1470,1471],"Relapsed AL Amyloidosis","Refractory AL Amyloidosis","Light Chain Amyloidosis","Amyloidosis",[1452],{"trials":1474,"activeCount":97},[],{"trials":1476,"activeCount":97},[],{"trials":1478,"activeCount":97},[],{"intervention":1480,"totalTrials":428,"cells":1481},"ALXN2420",{"EARLY_PHASE1":1482,"PHASE1":1484,"PHASE2":1486,"PHASE3":1498,"PHASE4":1500,"NA":1502},{"trials":1483,"activeCount":97},[],{"trials":1485,"activeCount":97},[],{"trials":1487,"activeCount":428,"soonestReadout":1492},[1488],{"nctId":1489,"briefTitle":1490,"status":163,"phases":1491,"primaryCompletion":1492,"completion":1493,"start":1494,"enrollment":9,"conditions":1495,"interventions":1497},"NCT07037420","ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly",[87],"2027-01-08","2027-11-11","2025-10-28",[1496],"Acromegaly",[1480],{"trials":1499,"activeCount":97},[],{"trials":1501,"activeCount":97},[],{"trials":1503,"activeCount":97},[],{"intervention":1505,"totalTrials":428,"cells":1506},"Tarperprumig",{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1511,"PHASE3":1522,"PHASE4":1524,"NA":1526},{"trials":1508,"activeCount":97},[],{"trials":1510,"activeCount":97},[],{"trials":1512,"activeCount":428,"soonestReadout":1403},[1513],{"nctId":1514,"briefTitle":1515,"status":163,"phases":1516,"primaryCompletion":1403,"completion":1517,"start":1518,"enrollment":391,"conditions":1519,"interventions":1521},"NCT07160608","Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis",[87],"2028-02-14","2025-11-26",[1520],"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",[1505],{"trials":1523,"activeCount":97},[],{"trials":1525,"activeCount":97},[],{"trials":1527,"activeCount":97},[],{"intervention":1529,"totalTrials":428,"cells":1530},"ALXN2350",{"EARLY_PHASE1":1531,"PHASE1":1533,"PHASE2":1535,"PHASE3":1546,"PHASE4":1548,"NA":1550},{"trials":1532,"activeCount":97},[],{"trials":1534,"activeCount":97},[],{"trials":1536,"activeCount":428,"soonestReadout":1541},[1537],{"nctId":1538,"briefTitle":1539,"status":163,"phases":1540,"primaryCompletion":1541,"completion":1541,"start":1542,"enrollment":611,"conditions":1543,"interventions":1545},"NCT07218887","ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy",[86,87],"2032-01-27","2025-10-24",[1544],"BAG3 Mutation Associated Dilated Cardiomyopathy",[1529],{"trials":1547,"activeCount":97},[],{"trials":1549,"activeCount":97},[],{"trials":1551,"activeCount":97},[],{"intervention":1553,"totalTrials":428,"cells":1554},"ALXN2230",{"EARLY_PHASE1":1555,"PHASE1":1557,"PHASE2":1568,"PHASE3":1570,"PHASE4":1572,"NA":1574},{"trials":1556,"activeCount":97},[],{"trials":1558,"activeCount":428,"soonestReadout":1563},[1559],{"nctId":1560,"briefTitle":1561,"status":163,"phases":1562,"primaryCompletion":1563,"completion":1563,"start":1564,"enrollment":1394,"conditions":1565,"interventions":1567},"NCT07352423","Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants",[86],"2026-12-23","2026-03-26",[1566],"Healthy Adult Participants",[1553],{"trials":1569,"activeCount":97},[],{"trials":1571,"activeCount":97},[],{"trials":1573,"activeCount":97},[],{"trials":1575,"activeCount":97},[],{"intervention":700,"totalTrials":428,"cells":1577},{"EARLY_PHASE1":1578,"PHASE1":1580,"PHASE2":1582,"PHASE3":1584,"PHASE4":1586,"NA":1588},{"trials":1579,"activeCount":97},[],{"trials":1581,"activeCount":97},[],{"trials":1583,"activeCount":97},[],{"trials":1585,"activeCount":97},[],{"trials":1587,"activeCount":97},[],{"trials":1589,"activeCount":428,"soonestReadout":695},[1590],{"nctId":692,"briefTitle":693,"status":235,"phases":1591,"primaryCompletion":695,"completion":695,"start":696,"enrollment":697,"conditions":1592,"interventions":1593},[],[18,32],[481,700],{"intervention":1595,"totalTrials":428,"cells":1596},"hLB-001",{"EARLY_PHASE1":1597,"PHASE1":1599,"PHASE2":1601,"PHASE3":1603,"PHASE4":1605,"NA":1607},{"trials":1598,"activeCount":97},[],{"trials":1600,"activeCount":97},[],{"trials":1602,"activeCount":97},[],{"trials":1604,"activeCount":97},[],{"trials":1606,"activeCount":97},[],{"trials":1608,"activeCount":428,"soonestReadout":1613},[1609],{"nctId":1610,"briefTitle":1611,"status":235,"phases":1612,"primaryCompletion":1613,"completion":1613,"start":1614,"enrollment":716,"conditions":1615,"interventions":1617},"NCT05506254","Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy",[],"2037-01-01","2022-07-15",[1616],"Methylmalonic Acidemia",[1595],{"intervention":1619,"totalTrials":428,"cells":1620},"Ultomiris",{"EARLY_PHASE1":1621,"PHASE1":1623,"PHASE2":1625,"PHASE3":1627,"PHASE4":1629,"NA":1631},{"trials":1622,"activeCount":97},[],{"trials":1624,"activeCount":97},[],{"trials":1626,"activeCount":97},[],{"trials":1628,"activeCount":97},[],{"trials":1630,"activeCount":97},[],{"trials":1632,"activeCount":428,"soonestReadout":1637},[1633],{"nctId":1634,"briefTitle":1635,"status":163,"phases":1636,"primaryCompletion":1637,"completion":1637,"start":1638,"enrollment":391,"conditions":1639,"interventions":1643},"NCT06312644","Study of Ultomiris® (Ravulizumab) Safety in Pregnancy",[],"2034-07-11","2024-12-16",[1640,1641,265,295,1339,1642],"Ultomiris-exposed Pregnant\u002F Postpartum","Pregnancy","Neuromyelitis Optica Spectrum Disorder (NMOSD)",[1619],{"intervention":1645,"totalTrials":405,"cells":1646},"Rituximab",{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1651,"PHASE3":1668,"PHASE4":1670,"NA":1685},{"trials":1648,"activeCount":97},[],{"trials":1650,"activeCount":97},[],{"trials":1652,"activeCount":97},[1653],{"nctId":1654,"briefTitle":1655,"status":103,"phases":1656,"primaryCompletion":1657,"completion":1657,"start":1658,"enrollment":1659,"conditions":1660,"interventions":1666},"NCT01994382","Phase 1\u002F2a Dose Escalation Study in Participants With CLL, SLL, or NHL",[86,87],"2020-12-15","2013-08-30",260,[1661,1662,1663,1664,1665],"Follicular Lymphoma (FL\u002FIndolent NHL)","Aggressive NHL (a NHL)","Chronic Lymphocytic Leukemia (CLL) \u002F Small Lymphocytic Lymphoma (SLL)","T-cell Lymphoma (PTCL and CTCL)","B-cell Non Hodgkin Lymphoma (NHL)",[1667,1645],"Cerdulatinib",{"trials":1669,"activeCount":97},[],{"trials":1671,"activeCount":97},[1672],{"nctId":1673,"briefTitle":1674,"status":913,"phases":1675,"primaryCompletion":1676,"completion":1676,"start":1677,"enrollment":97,"conditions":1678,"interventions":1679},"NCT06015750","Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia",[89],"2030-03-13","2026-07-29",[21],[1680,1681,1682,1683,1684],"methotrexate","rituximab","bortezomib","IVIg","Folic Acid",{"trials":1686,"activeCount":97},[],{"intervention":1688,"totalTrials":405,"cells":1689},"andexanet alfa",{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1694,"PHASE3":1706,"PHASE4":1708,"NA":1722},{"trials":1691,"activeCount":97},[],{"trials":1693,"activeCount":97},[],{"trials":1695,"activeCount":97},[1696],{"nctId":1697,"briefTitle":1698,"status":116,"phases":1699,"primaryCompletion":1700,"completion":1701,"start":1702,"enrollment":28,"conditions":1703,"interventions":1705},"NCT04233073","Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery",[87],"2021-11-23","2022-01-25","2021-06-27",[1704],"Surgery",[1688],{"trials":1707,"activeCount":97},[],{"trials":1709,"activeCount":97},[1710],{"nctId":1711,"briefTitle":1712,"status":103,"phases":1713,"primaryCompletion":1714,"completion":1715,"start":1716,"enrollment":1717,"conditions":1718,"interventions":1720},"NCT03661528","Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor",[89],"2023-05-27","2023-08-09","2019-06-06",530,[1719],"Acute Intracranial Hemorrhage",[1688,1721],"Usual Care",{"trials":1723,"activeCount":97},[],{"intervention":1680,"totalTrials":428,"cells":1725},{"EARLY_PHASE1":1726,"PHASE1":1728,"PHASE2":1730,"PHASE3":1732,"PHASE4":1734,"NA":1740},{"trials":1727,"activeCount":97},[],{"trials":1729,"activeCount":97},[],{"trials":1731,"activeCount":97},[],{"trials":1733,"activeCount":97},[],{"trials":1735,"activeCount":97},[1736],{"nctId":1673,"briefTitle":1674,"status":913,"phases":1737,"primaryCompletion":1676,"completion":1676,"start":1677,"enrollment":97,"conditions":1738,"interventions":1739},[89],[21],[1680,1681,1682,1683,1684],{"trials":1741,"activeCount":97},[],{"intervention":1682,"totalTrials":428,"cells":1743},{"EARLY_PHASE1":1744,"PHASE1":1746,"PHASE2":1748,"PHASE3":1750,"PHASE4":1752,"NA":1758},{"trials":1745,"activeCount":97},[],{"trials":1747,"activeCount":97},[],{"trials":1749,"activeCount":97},[],{"trials":1751,"activeCount":97},[],{"trials":1753,"activeCount":97},[1754],{"nctId":1673,"briefTitle":1674,"status":913,"phases":1755,"primaryCompletion":1676,"completion":1676,"start":1677,"enrollment":97,"conditions":1756,"interventions":1757},[89],[21],[1680,1681,1682,1683,1684],{"trials":1759,"activeCount":97},[],{"intervention":1683,"totalTrials":428,"cells":1761},{"EARLY_PHASE1":1762,"PHASE1":1764,"PHASE2":1766,"PHASE3":1768,"PHASE4":1770,"NA":1776},{"trials":1763,"activeCount":97},[],{"trials":1765,"activeCount":97},[],{"trials":1767,"activeCount":97},[],{"trials":1769,"activeCount":97},[],{"trials":1771,"activeCount":97},[1772],{"nctId":1673,"briefTitle":1674,"status":913,"phases":1773,"primaryCompletion":1676,"completion":1676,"start":1677,"enrollment":97,"conditions":1774,"interventions":1775},[89],[21],[1680,1681,1682,1683,1684],{"trials":1777,"activeCount":97},[],{"intervention":1684,"totalTrials":428,"cells":1779},{"EARLY_PHASE1":1780,"PHASE1":1782,"PHASE2":1784,"PHASE3":1786,"PHASE4":1788,"NA":1794},{"trials":1781,"activeCount":97},[],{"trials":1783,"activeCount":97},[],{"trials":1785,"activeCount":97},[],{"trials":1787,"activeCount":97},[],{"trials":1789,"activeCount":97},[1790],{"nctId":1673,"briefTitle":1674,"status":913,"phases":1791,"primaryCompletion":1676,"completion":1676,"start":1677,"enrollment":97,"conditions":1792,"interventions":1793},[89],[21],[1680,1681,1682,1683,1684],{"trials":1795,"activeCount":97},[],{"intervention":1721,"totalTrials":428,"cells":1797},{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1804,"PHASE4":1806,"NA":1812},{"trials":1799,"activeCount":97},[],{"trials":1801,"activeCount":97},[],{"trials":1803,"activeCount":97},[],{"trials":1805,"activeCount":97},[],{"trials":1807,"activeCount":97},[1808],{"nctId":1711,"briefTitle":1712,"status":103,"phases":1809,"primaryCompletion":1714,"completion":1715,"start":1716,"enrollment":1717,"conditions":1810,"interventions":1811},[89],[1719],[1688,1721],{"trials":1813,"activeCount":97},[],{"intervention":231,"totalTrials":428,"cells":1815},{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1822,"PHASE4":1828,"NA":1830},{"trials":1817,"activeCount":97},[],{"trials":1819,"activeCount":97},[],{"trials":1821,"activeCount":97},[],{"trials":1823,"activeCount":97},[1824],{"nctId":222,"briefTitle":223,"status":103,"phases":1825,"primaryCompletion":225,"completion":226,"start":227,"enrollment":228,"conditions":1826,"interventions":1827},[88],[18],[231,75],{"trials":1829,"activeCount":97},[],{"trials":1831,"activeCount":97},[],{"intervention":667,"totalTrials":428,"cells":1833},{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1840,"PHASE4":1846,"NA":1848},{"trials":1835,"activeCount":97},[],{"trials":1837,"activeCount":97},[],{"trials":1839,"activeCount":97},[],{"trials":1841,"activeCount":97},[1842],{"nctId":658,"briefTitle":659,"status":103,"phases":1843,"primaryCompletion":661,"completion":662,"start":663,"enrollment":664,"conditions":1844,"interventions":1845},[88],[18],[481,667],{"trials":1847,"activeCount":97},[],{"trials":1849,"activeCount":97},[],{"intervention":1851,"totalTrials":428,"cells":1852},"Standard of Care",{"EARLY_PHASE1":1853,"PHASE1":1855,"PHASE2":1857,"PHASE3":1859,"PHASE4":1870,"NA":1872},{"trials":1854,"activeCount":97},[],{"trials":1856,"activeCount":97},[],{"trials":1858,"activeCount":97},[],{"trials":1860,"activeCount":97},[1861],{"nctId":1862,"briefTitle":1863,"status":116,"phases":1864,"primaryCompletion":1865,"completion":1865,"start":1866,"enrollment":414,"conditions":1867,"interventions":1868},"NCT05047523","Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease",[88],"2023-06-26","2021-09-13",[27],[1869,1851],"ALXN1840",{"trials":1871,"activeCount":97},[],{"trials":1873,"activeCount":97},[],{"intervention":1875,"totalTrials":428,"cells":1876},"ALXN2060",{"EARLY_PHASE1":1877,"PHASE1":1879,"PHASE2":1881,"PHASE3":1883,"PHASE4":1895,"NA":1897},{"trials":1878,"activeCount":97},[],{"trials":1880,"activeCount":97},[],{"trials":1882,"activeCount":97},[],{"trials":1884,"activeCount":97},[1885],{"nctId":1886,"briefTitle":1887,"status":103,"phases":1888,"primaryCompletion":1889,"completion":1890,"start":1891,"enrollment":775,"conditions":1892,"interventions":1894},"NCT04622046","A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM",[88],"2023-11-08","2025-08-21","2020-11-13",[1893],"Symptomatic Transthyretin Amyloid Cardiomyopathy",[1875],{"trials":1896,"activeCount":97},[],{"trials":1898,"activeCount":97},[],{"intervention":1900,"totalTrials":428,"cells":1901},"pexelizumab",{"EARLY_PHASE1":1902,"PHASE1":1904,"PHASE2":1906,"PHASE3":1908,"PHASE4":1921,"NA":1923},{"trials":1903,"activeCount":97},[],{"trials":1905,"activeCount":97},[],{"trials":1907,"activeCount":97},[],{"trials":1909,"activeCount":97},[1910],{"nctId":1911,"briefTitle":1912,"status":103,"phases":1913,"primaryCompletion":1914,"start":1915,"enrollment":1916,"conditions":1917,"interventions":1920},"NCT00048308","Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass",[88],"2003-03","2002-01",3000,[1918,1919],"Cardio-pulmonary Bypass","Coronary Artery Bypass Graft",[1900],{"trials":1922,"activeCount":97},[],{"trials":1924,"activeCount":97},[],{"intervention":1926,"totalTrials":428,"cells":1927},"SoC Therapy",{"EARLY_PHASE1":1928,"PHASE1":1930,"PHASE2":1932,"PHASE3":1934,"PHASE4":1944,"NA":1946},{"trials":1929,"activeCount":97},[],{"trials":1931,"activeCount":97},[],{"trials":1933,"activeCount":97},[],{"trials":1935,"activeCount":97},[1936],{"nctId":1937,"briefTitle":1938,"status":116,"phases":1939,"primaryCompletion":1940,"completion":1940,"start":312,"enrollment":1941,"conditions":1942,"interventions":1943},"NCT03403205","Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease",[88],"2023-06-30",214,[27],[1869,1926],{"trials":1945,"activeCount":97},[],{"trials":1947,"activeCount":97},[],{"intervention":1949,"totalTrials":428,"cells":1950},"Andexanet",{"EARLY_PHASE1":1951,"PHASE1":1953,"PHASE2":1955,"PHASE3":1957,"PHASE4":1969,"NA":1971},{"trials":1952,"activeCount":97},[],{"trials":1954,"activeCount":97},[],{"trials":1956,"activeCount":97},[],{"trials":1958,"activeCount":97},[1959],{"nctId":1960,"briefTitle":1961,"status":103,"phases":1962,"primaryCompletion":1963,"completion":1963,"start":1964,"enrollment":1965,"conditions":1966,"interventions":1968},"NCT02329327","A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)",[88],"2020-09-24","2015-04-10",479,[1967],"Bleeding",[1949],{"trials":1970,"activeCount":97},[],{"trials":1972,"activeCount":97},[],{"intervention":1974,"totalTrials":428,"cells":1975},"pexelizumab in conjunction with CABG",{"EARLY_PHASE1":1976,"PHASE1":1978,"PHASE2":1980,"PHASE3":1982,"PHASE4":1994,"NA":1996},{"trials":1977,"activeCount":97},[],{"trials":1979,"activeCount":97},[],{"trials":1981,"activeCount":97},[],{"trials":1983,"activeCount":97},[1984],{"nctId":1985,"briefTitle":1986,"status":103,"phases":1987,"primaryCompletion":1988,"completion":1988,"start":1989,"enrollment":1990,"conditions":1991,"interventions":1993},"NCT00088179","Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)",[88],"2005-10","2004-07",4000,[1992],"Coronary Artery Disease",[1974],{"trials":1995,"activeCount":97},[],{"trials":1997,"activeCount":97},[],{"intervention":1999,"totalTrials":859,"cells":2000},"ALXN2050",{"EARLY_PHASE1":2001,"PHASE1":2003,"PHASE2":2076,"PHASE3":2107,"PHASE4":2109,"NA":2111},{"trials":2002,"activeCount":97},[],{"trials":2004,"activeCount":97},[2005,2014,2024,2032,2041,2050,2059,2068],{"nctId":2006,"briefTitle":2007,"status":103,"phases":2008,"primaryCompletion":2009,"completion":2009,"start":2010,"enrollment":2011,"conditions":2012,"interventions":2013},"NCT05047458","A Study of Single-dose ALXN2050 in Healthy Adults",[86],"2018-04-13","2017-11-28",28,[15],[1999],{"nctId":2015,"briefTitle":2016,"status":103,"phases":2017,"primaryCompletion":2018,"completion":2019,"start":2020,"enrollment":414,"conditions":2021,"interventions":2023},"NCT04623710","Study of ALXN2050 in Participants With Renal Impairment",[86],"2022-02-18","2022-03-21","2021-07-08",[2022,15],"Renal Impairment",[1999],{"nctId":2025,"briefTitle":2026,"status":103,"phases":2027,"primaryCompletion":2028,"completion":2028,"start":2029,"enrollment":565,"conditions":2030,"interventions":2031},"NCT05047484","A Study of Multiple Doses of ALXN2050 in Healthy Adults",[86],"2019-07-23","2019-01-07",[15],[1999],{"nctId":2033,"briefTitle":2034,"status":103,"phases":2035,"primaryCompletion":440,"completion":440,"start":2036,"enrollment":22,"conditions":2037,"interventions":2038},"NCT04933682","Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants",[86],"2021-06-23",[15],[1999,2039,2040],"Fluconazole","Rifampin",{"nctId":2042,"briefTitle":2043,"status":116,"phases":2044,"primaryCompletion":2045,"completion":2045,"start":2046,"enrollment":133,"conditions":2047,"interventions":2049},"NCT05259085","Study of ALXN2050 in Participants With Hepatic Impairment",[86],"2024-08-12","2022-04-07",[2048,15],"Impaired Hepatic Function",[1999],{"nctId":2051,"briefTitle":2052,"status":103,"phases":2053,"primaryCompletion":2054,"completion":2054,"start":2055,"enrollment":2056,"conditions":2057,"interventions":2058},"NCT04660890","A Study of the Cardiac Effects of ALXN2050 in Healthy Adults",[86],"2021-03-16","2020-12-12",39,[15],[1999,537],{"nctId":2060,"briefTitle":2061,"status":103,"phases":2062,"primaryCompletion":2019,"completion":2019,"start":2063,"enrollment":2064,"conditions":2065,"interventions":2066},"NCT05202145","Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants",[86],"2022-01-11",61,[15],[1999,577,578,2067],"MMF",{"nctId":2069,"briefTitle":2070,"status":103,"phases":2071,"primaryCompletion":2072,"completion":2072,"start":2073,"enrollment":345,"conditions":2074,"interventions":2075},"NCT04952545","Study of ALXN2050 in Healthy Adult Participants of Japanese Descent",[86],"2021-09-07","2021-07-09",[15],[1999],{"trials":2077,"activeCount":97},[2078,2088,2097],{"nctId":2079,"briefTitle":2080,"status":116,"phases":2081,"primaryCompletion":2082,"completion":2083,"start":2084,"enrollment":2085,"conditions":2086,"interventions":2087},"NCT05218096","Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis",[87],"2023-11-30","2024-04-03","2022-04-27",70,[30,1188],[1999],{"nctId":2089,"briefTitle":2090,"status":116,"phases":2091,"primaryCompletion":2092,"completion":2093,"start":2094,"enrollment":1130,"conditions":2095,"interventions":2096},"NCT04170023","Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy",[87],"2023-04-27","2024-03-20","2019-12-16",[265],[1999],{"nctId":2098,"briefTitle":2099,"status":116,"phases":2100,"primaryCompletion":2101,"completion":2101,"start":2102,"enrollment":2103,"conditions":2104,"interventions":2106},"NCT05097989","Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)",[87],"2024-12-09","2022-01-14",100,[123,124,169,2105],"LN",[1999],{"trials":2108,"activeCount":97},[],{"trials":2110,"activeCount":97},[],{"trials":2112,"activeCount":97},[],{"intervention":2114,"totalTrials":36,"cells":2115},"ALXN1830",{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2137,"PHASE3":2186,"PHASE4":2188,"NA":2190},{"trials":2117,"activeCount":97},[],{"trials":2119,"activeCount":97},[2120,2129],{"nctId":2121,"briefTitle":2122,"status":116,"phases":2123,"primaryCompletion":2124,"completion":2125,"start":2126,"enrollment":303,"conditions":2127,"interventions":2128},"NCT04730804","A Study of ALXN1830 in Healthy Adult Participants",[86],"2021-12-14","2022-01-04","2021-03-17",[15],[2114],{"nctId":2130,"briefTitle":2131,"status":116,"phases":2132,"primaryCompletion":2133,"completion":2133,"start":2134,"enrollment":25,"conditions":2135,"interventions":2136},"NCT05254613","A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants",[86],"2021-01-22","2019-11-12",[15],[2114],{"trials":2138,"activeCount":97},[2139,2148,2158,2166,2175],{"nctId":2140,"briefTitle":2141,"status":913,"phases":2142,"primaryCompletion":2143,"completion":2144,"start":2145,"enrollment":97,"conditions":2146,"interventions":2147},"NCT04982289","Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis",[87],"2023-01-31","2024-01-31","2022-01-01",[30],[2114],{"nctId":2149,"briefTitle":2150,"status":913,"phases":2151,"primaryCompletion":2152,"completion":2153,"start":2154,"enrollment":97,"conditions":2155,"interventions":2157},"NCT04256148","ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia",[87],"2022-10-30","2023-04-30","2021-07",[2156],"Warm Autoimmune Hemolytic Anemia",[2114],{"nctId":2159,"briefTitle":2160,"status":913,"phases":2161,"primaryCompletion":2162,"completion":2163,"start":2145,"enrollment":97,"conditions":2164,"interventions":2165},"NCT04956276","Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia",[87],"2022-07-31","2024-07-31",[2156],[2114],{"nctId":2167,"briefTitle":2168,"status":116,"phases":2169,"primaryCompletion":2170,"completion":2171,"start":2172,"enrollment":33,"conditions":2173,"interventions":2174},"NCT03075878","A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)",[86,87],"2019-04-15","2019-08-06","2018-01-10",[2156],[2114],{"nctId":2176,"briefTitle":2177,"status":116,"phases":2178,"primaryCompletion":2179,"completion":2179,"start":2180,"enrollment":33,"conditions":2181,"interventions":2185},"NCT03075904","A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)",[86,87],"2019-01-16","2017-07-18",[2182,2183,2184],"Pemphigus","Pemphigus Vulgaris","Pemphigus Foliaceus",[2114],{"trials":2187,"activeCount":97},[],{"trials":2189,"activeCount":97},[],{"trials":2191,"activeCount":97},[],{"intervention":2193,"totalTrials":716,"cells":2194},"ALXN1210",{"EARLY_PHASE1":2195,"PHASE1":2197,"PHASE2":2223,"PHASE3":2234,"PHASE4":2236,"NA":2238},{"trials":2196,"activeCount":97},[],{"trials":2198,"activeCount":97},[2199,2207,2215],{"nctId":2200,"briefTitle":2201,"status":103,"phases":2202,"primaryCompletion":2203,"completion":2203,"start":2204,"enrollment":22,"conditions":2205,"interventions":2206},"NCT05288673","A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants",[86],"2016-09-01","2015-07-28",[15],[2193],{"nctId":2208,"briefTitle":2209,"status":103,"phases":2210,"primaryCompletion":2211,"completion":2211,"start":2212,"enrollment":826,"conditions":2213,"interventions":2214},"NCT05288660","A Study of a Single Dose of ALXN1210 in Healthy Participants",[86],"2015-03-13","2014-08-27",[15],[2193],{"nctId":2216,"briefTitle":2217,"status":103,"phases":2218,"primaryCompletion":2219,"completion":2219,"start":2220,"enrollment":22,"conditions":2221,"interventions":2222},"NCT05288816","A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants",[86],"2017-07-05","2016-04-18",[15],[2193],{"trials":2224,"activeCount":97},[2225],{"nctId":2226,"briefTitle":2227,"status":103,"phases":2228,"primaryCompletion":2229,"completion":2230,"start":2231,"enrollment":313,"conditions":2232,"interventions":2233},"NCT02598583","Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)",[86,87],"2016-07-14","2021-03-11","2015-11-12",[32],[2193],{"trials":2235,"activeCount":97},[],{"trials":2237,"activeCount":97},[],{"trials":2239,"activeCount":97},[],{"intervention":2241,"totalTrials":716,"cells":2242},"Elvucitabine",{"EARLY_PHASE1":2243,"PHASE1":2245,"PHASE2":2247,"PHASE3":2288,"PHASE4":2290,"NA":2292},{"trials":2244,"activeCount":97},[],{"trials":2246,"activeCount":97},[],{"trials":2248,"activeCount":97},[2249,2260,2272,2280],{"nctId":2250,"briefTitle":2251,"status":103,"phases":2252,"primaryCompletion":2253,"completion":836,"start":2254,"enrollment":716,"conditions":2255,"interventions":2257},"NCT00380159","Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A",[87],"2008-12","2006-09",[2256],"Human Immunodeficiency Virus (HIV)-1 Infection",[2241,2258,2259],"Lamivudine","Emtricitabine",{"nctId":2261,"briefTitle":2262,"status":103,"phases":2263,"primaryCompletion":2264,"completion":891,"start":2265,"enrollment":2266,"conditions":2267,"interventions":2269},"NCT00350272","Elvucitabine\u002FEfavirenz\u002FTenofovir Versus Lamivudine\u002FEfavirenz\u002FTenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants",[87],"2007-08","2006-05",76,[2268],"HIV Infections",[2241,2258,2270,2271],"Tenofovir","Efavirenz",{"nctId":2273,"briefTitle":2274,"status":103,"phases":2275,"primaryCompletion":2276,"completion":2276,"start":2277,"enrollment":36,"conditions":2278,"interventions":2279},"NCT00675844","An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment",[87],"2010-03","2008-05",[2268],[2241],{"nctId":2281,"briefTitle":2282,"status":103,"phases":2283,"primaryCompletion":2284,"completion":2284,"start":2285,"enrollment":345,"conditions":2286,"interventions":2287},"NCT00312039","Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation",[86,87],"2007-10-31","2006-03-31",[2268],[2241,2258],{"trials":2289,"activeCount":97},[],{"trials":2291,"activeCount":97},[],{"trials":2293,"activeCount":97},[],{"intervention":2258,"totalTrials":716,"cells":2295},{"EARLY_PHASE1":2296,"PHASE1":2298,"PHASE2":2300,"PHASE3":2325,"PHASE4":2327,"NA":2329},{"trials":2297,"activeCount":97},[],{"trials":2299,"activeCount":97},[],{"trials":2301,"activeCount":97},[2302,2306,2310,2321],{"nctId":2250,"briefTitle":2251,"status":103,"phases":2303,"primaryCompletion":2253,"completion":836,"start":2254,"enrollment":716,"conditions":2304,"interventions":2305},[87],[2256],[2241,2258,2259],{"nctId":2261,"briefTitle":2262,"status":103,"phases":2307,"primaryCompletion":2264,"completion":891,"start":2265,"enrollment":2266,"conditions":2308,"interventions":2309},[87],[2268],[2241,2258,2270,2271],{"nctId":2311,"briefTitle":2312,"status":103,"phases":2313,"primaryCompletion":2314,"completion":2314,"start":2315,"enrollment":2316,"conditions":2317,"interventions":2319},"NCT00034359","Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection",[87],"2003-01","2002-02",79,[2318],"Hepatitis B, Chronic",[2320,2258],"ACH-126,443",{"nctId":2281,"briefTitle":2282,"status":103,"phases":2322,"primaryCompletion":2284,"completion":2284,"start":2285,"enrollment":345,"conditions":2323,"interventions":2324},[86,87],[2268],[2241,2258],{"trials":2326,"activeCount":97},[],{"trials":2328,"activeCount":97},[],{"trials":2330,"activeCount":97},[],{"intervention":2332,"totalTrials":756,"cells":2333},"Ribavirin",{"EARLY_PHASE1":2334,"PHASE1":2336,"PHASE2":2348,"PHASE3":2372,"PHASE4":2374,"NA":2376},{"trials":2335,"activeCount":97},[],{"trials":2337,"activeCount":97},[2338],{"nctId":2339,"briefTitle":2340,"status":103,"phases":2341,"primaryCompletion":2342,"completion":2342,"start":2343,"enrollment":33,"conditions":2344,"interventions":2346},"NCT01700179","Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants",[86],"2013-09","2012-09",[2345],"Chronic Hepatitis C Infection",[2347,2332],"ACH-0143102",{"trials":2349,"activeCount":97},[2350,2361],{"nctId":2351,"briefTitle":2352,"status":103,"phases":2353,"primaryCompletion":2354,"completion":1172,"start":2355,"enrollment":739,"conditions":2356,"interventions":2358},"NCT01849562","Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants",[87],"2013-11","2013-04",[2357],"Hepatitis C, Chronic",[2359,2360,2332],"Sovaprevir","ACH-3102",{"nctId":2362,"briefTitle":2363,"status":103,"phases":2364,"primaryCompletion":2365,"completion":2355,"start":1109,"enrollment":2366,"conditions":2367,"interventions":2369},"NCT01180790","Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants",[87],"2012-03",122,[2368],"Hepatitis C",[2370,2370,2370,2371,2332],"ACH-0141625","Pegylated Interferon alpha-2a",{"trials":2373,"activeCount":97},[],{"trials":2375,"activeCount":97},[],{"trials":2377,"activeCount":97},[],{"intervention":2379,"totalTrials":405,"cells":2380},"SBC-103",{"EARLY_PHASE1":2381,"PHASE1":2383,"PHASE2":2385,"PHASE3":2406,"PHASE4":2408,"NA":2410},{"trials":2382,"activeCount":97},[],{"trials":2384,"activeCount":97},[],{"trials":2386,"activeCount":97},[2387,2396],{"nctId":2388,"briefTitle":2389,"status":103,"phases":2390,"primaryCompletion":2391,"completion":2391,"start":2392,"enrollment":859,"conditions":2393,"interventions":2395},"NCT02324049","Safety, Pharmacokinetics, and Pharmacodynamics\u002FEfficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)",[86,87],"2017-10-16","2015-01-22",[2394],"Mucopolysaccharidosis IIIB",[2379],{"nctId":2397,"briefTitle":2398,"status":116,"phases":2399,"primaryCompletion":2400,"completion":2400,"start":2401,"enrollment":756,"conditions":2402,"interventions":2405},"NCT02618512","A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics\u002FEfficacy of SBC-103 Administered Intravenously",[86,87],"2017-08-18","2015-10-15",[2403,2404],"Mucopolysaccharidosis III, Type B (MPS IIIB)","Sanfilippo B",[2379],{"trials":2407,"activeCount":97},[],{"trials":2409,"activeCount":97},[],{"trials":2411,"activeCount":97},[],{"intervention":2413,"totalTrials":405,"cells":2414},"Samalizumab",{"EARLY_PHASE1":2415,"PHASE1":2417,"PHASE2":2429,"PHASE3":2441,"PHASE4":2443,"NA":2445},{"trials":2416,"activeCount":97},[],{"trials":2418,"activeCount":97},[2419],{"nctId":2420,"briefTitle":2421,"status":116,"phases":2422,"primaryCompletion":2423,"completion":2424,"start":2425,"enrollment":28,"conditions":2426,"interventions":2428},"NCT02987504","Study of Samalizumab in Patients With Advanced Cancer",[86],"2017-09-12","2017-09-27","2016-11-17",[2427],"Advanced Solid Tumors",[2413],{"trials":2430,"activeCount":97},[2431],{"nctId":2432,"briefTitle":2433,"status":116,"phases":2434,"primaryCompletion":2435,"completion":2435,"start":2436,"enrollment":133,"conditions":2437,"interventions":2440},"NCT00648739","Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM",[86,87],"2010-12-14","2008-06-19",[2438,2439],"B-cell Chronic Lymphocytic Leukemia","Multiple Myeloma",[2413],{"trials":2442,"activeCount":97},[],{"trials":2444,"activeCount":97},[],{"trials":2446,"activeCount":97},[],{"intervention":2448,"totalTrials":405,"cells":2449},"Bertilimumab",{"EARLY_PHASE1":2450,"PHASE1":2452,"PHASE2":2454,"PHASE3":2476,"PHASE4":2478,"NA":2480},{"trials":2451,"activeCount":97},[],{"trials":2453,"activeCount":97},[],{"trials":2455,"activeCount":97},[2456,2467],{"nctId":2457,"briefTitle":2458,"status":116,"phases":2459,"primaryCompletion":2460,"completion":651,"start":2461,"enrollment":2462,"conditions":2463,"interventions":2466},"NCT01671956","Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis",[87],"2018-08-31","2015-07-31",32,[2464,2465],"Ulcerative Colitis, Active Moderate","Ulcerative Colitis, Active Severe",[2448],{"nctId":2468,"briefTitle":2469,"status":103,"phases":2470,"primaryCompletion":2471,"completion":2471,"start":2472,"enrollment":859,"conditions":2473,"interventions":2475},"NCT02226146","Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid",[87],"2018-04-30","2016-02-29",[2474],"Pemphigoid, Bullous",[2448],{"trials":2477,"activeCount":97},[],{"trials":2479,"activeCount":97},[],{"trials":2481,"activeCount":97},[],{"intervention":2483,"totalTrials":428,"cells":2484},"Study Drug- ALXN1007",{"EARLY_PHASE1":2485,"PHASE1":2487,"PHASE2":2489,"PHASE3":2498,"PHASE4":2500,"NA":2502},{"trials":2486,"activeCount":97},[],{"trials":2488,"activeCount":97},[],{"trials":2490,"activeCount":97},[2491],{"nctId":2492,"briefTitle":2493,"status":116,"phases":2494,"primaryCompletion":848,"completion":848,"start":1172,"enrollment":525,"conditions":2495,"interventions":2497},"NCT02128269","Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome",[87],[2496],"Antiphospholipid (aPL)-Positive",[2483],{"trials":2499,"activeCount":97},[],{"trials":2501,"activeCount":97},[],{"trials":2503,"activeCount":97},[],{"intervention":2505,"totalTrials":428,"cells":2506},"Bis-Choline Tetrathiomolybdate",{"EARLY_PHASE1":2507,"PHASE1":2509,"PHASE2":2511,"PHASE3":2522,"PHASE4":2524,"NA":2526},{"trials":2508,"activeCount":97},[],{"trials":2510,"activeCount":97},[],{"trials":2512,"activeCount":97},[2513],{"nctId":2514,"briefTitle":2515,"status":103,"phases":2516,"primaryCompletion":2517,"completion":2518,"start":2519,"enrollment":93,"conditions":2520,"interventions":2521},"NCT04422431","Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840",[87],"2022-05-21","2023-05-17","2020-12-02",[27],[2505],{"trials":2523,"activeCount":97},[],{"trials":2525,"activeCount":97},[],{"trials":2527,"activeCount":97},[],{"intervention":2259,"totalTrials":428,"cells":2529},{"EARLY_PHASE1":2530,"PHASE1":2532,"PHASE2":2534,"PHASE3":2540,"PHASE4":2542,"NA":2544},{"trials":2531,"activeCount":97},[],{"trials":2533,"activeCount":97},[],{"trials":2535,"activeCount":97},[2536],{"nctId":2250,"briefTitle":2251,"status":103,"phases":2537,"primaryCompletion":2253,"completion":836,"start":2254,"enrollment":716,"conditions":2538,"interventions":2539},[87],[2256],[2241,2258,2259],{"trials":2541,"activeCount":97},[],{"trials":2543,"activeCount":97},[],{"trials":2545,"activeCount":97},[],{"intervention":2547,"totalTrials":428,"cells":2548},"Sebelipase alfa 0.35 mg\u002Fkg",{"EARLY_PHASE1":2549,"PHASE1":2551,"PHASE2":2553,"PHASE3":2567,"PHASE4":2569,"NA":2571},{"trials":2550,"activeCount":97},[],{"trials":2552,"activeCount":97},[],{"trials":2554,"activeCount":97},[2555],{"nctId":2556,"briefTitle":2557,"status":103,"phases":2558,"primaryCompletion":2559,"completion":2559,"start":2560,"enrollment":525,"conditions":2561,"interventions":2564},"NCT01307098","Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency",[86,87],"2012-01-06","2011-04-25",[2562,24,2563],"Cholesterol Ester Storage Disease(CESD)","LAL-Deficiency",[2547,2565,2566],"Sebelipase alfa 1 mg\u002Fkg","Sebelipase alfa 3 mg\u002Fkg",{"trials":2568,"activeCount":97},[],{"trials":2570,"activeCount":97},[],{"trials":2572,"activeCount":97},[],{"intervention":2565,"totalTrials":428,"cells":2574},{"EARLY_PHASE1":2575,"PHASE1":2577,"PHASE2":2579,"PHASE3":2585,"PHASE4":2587,"NA":2589},{"trials":2576,"activeCount":97},[],{"trials":2578,"activeCount":97},[],{"trials":2580,"activeCount":97},[2581],{"nctId":2556,"briefTitle":2557,"status":103,"phases":2582,"primaryCompletion":2559,"completion":2559,"start":2560,"enrollment":525,"conditions":2583,"interventions":2584},[86,87],[2562,24,2563],[2547,2565,2566],{"trials":2586,"activeCount":97},[],{"trials":2588,"activeCount":97},[],{"trials":2590,"activeCount":97},[],{"intervention":2566,"totalTrials":428,"cells":2592},{"EARLY_PHASE1":2593,"PHASE1":2595,"PHASE2":2597,"PHASE3":2603,"PHASE4":2605,"NA":2607},{"trials":2594,"activeCount":97},[],{"trials":2596,"activeCount":97},[],{"trials":2598,"activeCount":97},[2599],{"nctId":2556,"briefTitle":2557,"status":103,"phases":2600,"primaryCompletion":2559,"completion":2559,"start":2560,"enrollment":525,"conditions":2601,"interventions":2602},[86,87],[2562,24,2563],[2547,2565,2566],{"trials":2604,"activeCount":97},[],{"trials":2606,"activeCount":97},[],{"trials":2608,"activeCount":97},[],{"intervention":2610,"totalTrials":428,"cells":2611},"ACH-0137171",{"EARLY_PHASE1":2612,"PHASE1":2614,"PHASE2":2616,"PHASE3":2627,"PHASE4":2629,"NA":2631},{"trials":2613,"activeCount":97},[],{"trials":2615,"activeCount":97},[],{"trials":2617,"activeCount":97},[2618],{"nctId":2619,"briefTitle":2620,"status":116,"phases":2621,"completion":2622,"start":2623,"enrollment":739,"conditions":2624,"interventions":2626},"NCT00401947","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection",[87],"2007-03-31","2006-11-30",[2625],"HCV Infection",[2610],{"trials":2628,"activeCount":97},[],{"trials":2630,"activeCount":97},[],{"trials":2632,"activeCount":97},[],{"intervention":2634,"totalTrials":428,"cells":2635},"AZP-3601",{"EARLY_PHASE1":2636,"PHASE1":2638,"PHASE2":2640,"PHASE3":2651,"PHASE4":2653,"NA":2655},{"trials":2637,"activeCount":97},[],{"trials":2639,"activeCount":97},[],{"trials":2641,"activeCount":97},[2642],{"nctId":2643,"briefTitle":2644,"status":103,"phases":2645,"primaryCompletion":2646,"completion":2646,"start":2647,"enrollment":2648,"conditions":2649,"interventions":2650},"NCT05239221","AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism",[86,87],"2022-08-23","2020-09-07",132,[1029],[2634],{"trials":2652,"activeCount":97},[],{"trials":2654,"activeCount":97},[],{"trials":2656,"activeCount":97},[],{"intervention":2658,"totalTrials":428,"cells":2659},"ACH126-443",{"EARLY_PHASE1":2660,"PHASE1":2662,"PHASE2":2664,"PHASE3":2673,"PHASE4":2675,"NA":2677},{"trials":2661,"activeCount":97},[],{"trials":2663,"activeCount":97},[],{"trials":2665,"activeCount":97},[2666],{"nctId":2667,"briefTitle":2668,"status":116,"phases":2669,"completion":2670,"enrollment":9,"conditions":2671,"interventions":2672},"NCT00040157","Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.",[87],"2003-05",[2268],[2658],{"trials":2674,"activeCount":97},[],{"trials":2676,"activeCount":97},[],{"trials":2678,"activeCount":97},[],{"intervention":2680,"totalTrials":428,"cells":2681},"ENB-0040",{"EARLY_PHASE1":2682,"PHASE1":2684,"PHASE2":2686,"PHASE3":2695,"PHASE4":2697,"NA":2699},{"trials":2683,"activeCount":97},[],{"trials":2685,"activeCount":97},[],{"trials":2687,"activeCount":97},[2688],{"nctId":2689,"briefTitle":2690,"status":913,"phases":2691,"primaryCompletion":2692,"completion":2692,"start":1087,"enrollment":97,"conditions":2693,"interventions":2694},"NCT00894075","Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)",[87],"2014-12",[21],[2680],{"trials":2696,"activeCount":97},[],{"trials":2698,"activeCount":97},[],{"trials":2700,"activeCount":97},[],{"intervention":2270,"totalTrials":428,"cells":2702},{"EARLY_PHASE1":2703,"PHASE1":2705,"PHASE2":2707,"PHASE3":2713,"PHASE4":2715,"NA":2717},{"trials":2704,"activeCount":97},[],{"trials":2706,"activeCount":97},[],{"trials":2708,"activeCount":97},[2709],{"nctId":2261,"briefTitle":2262,"status":103,"phases":2710,"primaryCompletion":2264,"completion":891,"start":2265,"enrollment":2266,"conditions":2711,"interventions":2712},[87],[2268],[2241,2258,2270,2271],{"trials":2714,"activeCount":97},[],{"trials":2716,"activeCount":97},[],{"trials":2718,"activeCount":97},[],{"intervention":2271,"totalTrials":428,"cells":2720},{"EARLY_PHASE1":2721,"PHASE1":2723,"PHASE2":2725,"PHASE3":2731,"PHASE4":2733,"NA":2735},{"trials":2722,"activeCount":97},[],{"trials":2724,"activeCount":97},[],{"trials":2726,"activeCount":97},[2727],{"nctId":2261,"briefTitle":2262,"status":103,"phases":2728,"primaryCompletion":2264,"completion":891,"start":2265,"enrollment":2266,"conditions":2729,"interventions":2730},[87],[2268],[2241,2258,2270,2271],{"trials":2732,"activeCount":97},[],{"trials":2734,"activeCount":97},[],{"trials":2736,"activeCount":97},[],{"intervention":2738,"totalTrials":428,"cells":2739},"ACH-0144471",{"EARLY_PHASE1":2740,"PHASE1":2742,"PHASE2":2744,"PHASE3":2753,"PHASE4":2755,"NA":2757},{"trials":2741,"activeCount":97},[],{"trials":2743,"activeCount":97},[],{"trials":2745,"activeCount":97},[2746],{"nctId":2747,"briefTitle":2748,"status":103,"phases":2749,"primaryCompletion":2125,"completion":2125,"start":2750,"enrollment":33,"conditions":2751,"interventions":2752},"NCT03181633","A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)",[87],"2017-06-22",[18],[2738],{"trials":2754,"activeCount":97},[],{"trials":2756,"activeCount":97},[],{"trials":2758,"activeCount":97},[],{"intervention":2359,"totalTrials":428,"cells":2760},{"EARLY_PHASE1":2761,"PHASE1":2763,"PHASE2":2765,"PHASE3":2771,"PHASE4":2773,"NA":2775},{"trials":2762,"activeCount":97},[],{"trials":2764,"activeCount":97},[],{"trials":2766,"activeCount":97},[2767],{"nctId":2351,"briefTitle":2352,"status":103,"phases":2768,"primaryCompletion":2354,"completion":1172,"start":2355,"enrollment":739,"conditions":2769,"interventions":2770},[87],[2357],[2359,2360,2332],{"trials":2772,"activeCount":97},[],{"trials":2774,"activeCount":97},[],{"trials":2776,"activeCount":97},[],{"intervention":2360,"totalTrials":428,"cells":2778},{"EARLY_PHASE1":2779,"PHASE1":2781,"PHASE2":2783,"PHASE3":2789,"PHASE4":2791,"NA":2793},{"trials":2780,"activeCount":97},[],{"trials":2782,"activeCount":97},[],{"trials":2784,"activeCount":97},[2785],{"nctId":2351,"briefTitle":2352,"status":103,"phases":2786,"primaryCompletion":2354,"completion":1172,"start":2355,"enrollment":739,"conditions":2787,"interventions":2788},[87],[2357],[2359,2360,2332],{"trials":2790,"activeCount":97},[],{"trials":2792,"activeCount":97},[],{"trials":2794,"activeCount":97},[],{"intervention":779,"totalTrials":428,"cells":2796},{"EARLY_PHASE1":2797,"PHASE1":2799,"PHASE2":2801,"PHASE3":2807,"PHASE4":2809,"NA":2811},{"trials":2798,"activeCount":97},[],{"trials":2800,"activeCount":97},[],{"trials":2802,"activeCount":97},[2803],{"nctId":770,"briefTitle":771,"status":103,"phases":2804,"primaryCompletion":773,"completion":773,"start":774,"enrollment":775,"conditions":2805,"interventions":2806},[87],[777],[47,779,780],{"trials":2808,"activeCount":97},[],{"trials":2810,"activeCount":97},[],{"trials":2812,"activeCount":97},[],{"intervention":780,"totalTrials":428,"cells":2814},{"EARLY_PHASE1":2815,"PHASE1":2817,"PHASE2":2819,"PHASE3":2825,"PHASE4":2827,"NA":2829},{"trials":2816,"activeCount":97},[],{"trials":2818,"activeCount":97},[],{"trials":2820,"activeCount":97},[2821],{"nctId":770,"briefTitle":771,"status":103,"phases":2822,"primaryCompletion":773,"completion":773,"start":774,"enrollment":775,"conditions":2823,"interventions":2824},[87],[777],[47,779,780],{"trials":2826,"activeCount":97},[],{"trials":2828,"activeCount":97},[],{"trials":2830,"activeCount":97},[],{"intervention":2832,"totalTrials":428,"cells":2833},"ACH126, 433",{"EARLY_PHASE1":2834,"PHASE1":2836,"PHASE2":2838,"PHASE3":2848,"PHASE4":2850,"NA":2852},{"trials":2835,"activeCount":97},[],{"trials":2837,"activeCount":97},[],{"trials":2839,"activeCount":97},[2840],{"nctId":2841,"briefTitle":2842,"status":116,"phases":2843,"completion":2670,"start":2844,"enrollment":1225,"conditions":2845,"interventions":2847},"NCT00040144","Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B",[87],"2002-07",[2846],"Chronic Hepatitis B",[2832],{"trials":2849,"activeCount":97},[],{"trials":2851,"activeCount":97},[],{"trials":2853,"activeCount":97},[],{"intervention":2855,"totalTrials":428,"cells":2856},"ALXN1007 10 mg\u002Fkg once weekly",{"EARLY_PHASE1":2857,"PHASE1":2859,"PHASE2":2861,"PHASE3":2875,"PHASE4":2877,"NA":2879},{"trials":2858,"activeCount":97},[],{"trials":2860,"activeCount":97},[],{"trials":2862,"activeCount":97},[2863],{"nctId":2864,"briefTitle":2865,"status":116,"phases":2866,"primaryCompletion":2867,"completion":2867,"start":2868,"enrollment":775,"conditions":2869,"interventions":2872},"NCT02245412","A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease",[87],"2017-02-27","2014-11-14",[2870,2871],"Acute Graft-Versus-Host Disease","GIGVHD",[2855,2873,2874],"ALXN1007 20 mg\u002Fkg once weekly","ALXN1007 20 mg\u002Fkg twice weekly",{"trials":2876,"activeCount":97},[],{"trials":2878,"activeCount":97},[],{"trials":2880,"activeCount":97},[],{"intervention":2873,"totalTrials":428,"cells":2882},{"EARLY_PHASE1":2883,"PHASE1":2885,"PHASE2":2887,"PHASE3":2893,"PHASE4":2895,"NA":2897},{"trials":2884,"activeCount":97},[],{"trials":2886,"activeCount":97},[],{"trials":2888,"activeCount":97},[2889],{"nctId":2864,"briefTitle":2865,"status":116,"phases":2890,"primaryCompletion":2867,"completion":2867,"start":2868,"enrollment":775,"conditions":2891,"interventions":2892},[87],[2870,2871],[2855,2873,2874],{"trials":2894,"activeCount":97},[],{"trials":2896,"activeCount":97},[],{"trials":2898,"activeCount":97},[],{"intervention":2874,"totalTrials":428,"cells":2900},{"EARLY_PHASE1":2901,"PHASE1":2903,"PHASE2":2905,"PHASE3":2911,"PHASE4":2913,"NA":2915},{"trials":2902,"activeCount":97},[],{"trials":2904,"activeCount":97},[],{"trials":2906,"activeCount":97},[2907],{"nctId":2864,"briefTitle":2865,"status":116,"phases":2908,"primaryCompletion":2867,"completion":2867,"start":2868,"enrollment":775,"conditions":2909,"interventions":2910},[87],[2870,2871],[2855,2873,2874],{"trials":2912,"activeCount":97},[],{"trials":2914,"activeCount":97},[],{"trials":2916,"activeCount":97},[],{"intervention":2320,"totalTrials":428,"cells":2918},{"EARLY_PHASE1":2919,"PHASE1":2921,"PHASE2":2923,"PHASE3":2929,"PHASE4":2931,"NA":2933},{"trials":2920,"activeCount":97},[],{"trials":2922,"activeCount":97},[],{"trials":2924,"activeCount":97},[2925],{"nctId":2311,"briefTitle":2312,"status":103,"phases":2926,"primaryCompletion":2314,"completion":2314,"start":2315,"enrollment":2316,"conditions":2927,"interventions":2928},[87],[2318],[2320,2258],{"trials":2930,"activeCount":97},[],{"trials":2932,"activeCount":97},[],{"trials":2934,"activeCount":97},[],{"intervention":2370,"totalTrials":428,"cells":2936},{"EARLY_PHASE1":2937,"PHASE1":2939,"PHASE2":2941,"PHASE3":2947,"PHASE4":2949,"NA":2951},{"trials":2938,"activeCount":97},[],{"trials":2940,"activeCount":97},[],{"trials":2942,"activeCount":97},[2943],{"nctId":2362,"briefTitle":2363,"status":103,"phases":2944,"primaryCompletion":2365,"completion":2355,"start":1109,"enrollment":2366,"conditions":2945,"interventions":2946},[87],[2368],[2370,2370,2370,2371,2332],{"trials":2948,"activeCount":97},[],{"trials":2950,"activeCount":97},[],{"trials":2952,"activeCount":97},[],{"intervention":2371,"totalTrials":428,"cells":2954},{"EARLY_PHASE1":2955,"PHASE1":2957,"PHASE2":2959,"PHASE3":2965,"PHASE4":2967,"NA":2969},{"trials":2956,"activeCount":97},[],{"trials":2958,"activeCount":97},[],{"trials":2960,"activeCount":97},[2961],{"nctId":2362,"briefTitle":2363,"status":103,"phases":2962,"primaryCompletion":2365,"completion":2355,"start":1109,"enrollment":2366,"conditions":2963,"interventions":2964},[87],[2368],[2370,2370,2370,2371,2332],{"trials":2966,"activeCount":97},[],{"trials":2968,"activeCount":97},[],{"trials":2970,"activeCount":97},[],{"intervention":2972,"totalTrials":428,"cells":2973},"ALXN1820",{"EARLY_PHASE1":2974,"PHASE1":2976,"PHASE2":2978,"PHASE3":2989,"PHASE4":2991,"NA":2993},{"trials":2975,"activeCount":97},[],{"trials":2977,"activeCount":97},[],{"trials":2979,"activeCount":97},[2980],{"nctId":2981,"briefTitle":2982,"status":116,"phases":2983,"primaryCompletion":2984,"completion":2984,"start":2985,"enrollment":405,"conditions":2986,"interventions":2988},"NCT05565092","Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease",[87],"2024-01-09","2023-02-22",[2987],"Sickle Cell Disease (SCD)",[2972],{"trials":2990,"activeCount":97},[],{"trials":2992,"activeCount":97},[],{"trials":2994,"activeCount":97},[],{"intervention":537,"totalTrials":756,"cells":2996},{"EARLY_PHASE1":2997,"PHASE1":2999,"PHASE2":3017,"PHASE3":3019,"PHASE4":3021,"NA":3023},{"trials":2998,"activeCount":97},[],{"trials":3000,"activeCount":97},[3001,3009,3013],{"nctId":3002,"briefTitle":3003,"status":103,"phases":3004,"primaryCompletion":3005,"completion":3005,"start":3006,"enrollment":1271,"conditions":3007,"interventions":3008},"NCT04560816","A Study of the Cardiac Effects of ALXN1840 in Healthy Adults",[86],"2021-03-24","2020-07-24",[15],[1869,537],{"nctId":529,"briefTitle":530,"status":103,"phases":3010,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":3011,"interventions":3012},[86],[15],[481,537],{"nctId":2051,"briefTitle":2052,"status":103,"phases":3014,"primaryCompletion":2054,"completion":2054,"start":2055,"enrollment":2056,"conditions":3015,"interventions":3016},[86],[15],[1999,537],{"trials":3018,"activeCount":97},[],{"trials":3020,"activeCount":97},[],{"trials":3022,"activeCount":97},[],{"trials":3024,"activeCount":97},[],{"intervention":581,"totalTrials":756,"cells":3026},{"EARLY_PHASE1":3027,"PHASE1":3029,"PHASE2":3053,"PHASE3":3055,"PHASE4":3057,"NA":3059},{"trials":3028,"activeCount":97},[],{"trials":3030,"activeCount":97},[3031,3041,3049],{"nctId":3032,"briefTitle":3033,"status":103,"phases":3034,"primaryCompletion":3035,"completion":3035,"start":3036,"enrollment":19,"conditions":3037,"interventions":3038},"NCT05319912","A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults",[86],"2014-05-29","2014-04-07",[15],[3039,3040,581],"ALXN1840 Enteric-coated","ALXN1840 Non-coated",{"nctId":3042,"briefTitle":3043,"status":103,"phases":3044,"primaryCompletion":3045,"completion":3045,"start":3046,"enrollment":19,"conditions":3047,"interventions":3048},"NCT05319899","A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults",[86],"2014-03-24","2014-01-20",[15],[1869,581],{"nctId":569,"briefTitle":570,"status":103,"phases":3050,"primaryCompletion":572,"completion":572,"start":573,"enrollment":574,"conditions":3051,"interventions":3052},[86],[15],[481,577,578,579,580,581],{"trials":3054,"activeCount":97},[],{"trials":3056,"activeCount":97},[],{"trials":3058,"activeCount":97},[],{"trials":3060,"activeCount":97},[],{"intervention":3062,"totalTrials":756,"cells":3063},"Rosuvastatin",{"EARLY_PHASE1":3064,"PHASE1":3066,"PHASE2":3098,"PHASE3":3100,"PHASE4":3102,"NA":3104},{"trials":3065,"activeCount":97},[],{"trials":3067,"activeCount":97},[3068,3078,3088],{"nctId":3069,"briefTitle":3070,"status":103,"phases":3071,"primaryCompletion":3072,"completion":3072,"start":3073,"enrollment":345,"conditions":3074,"interventions":3075},"NCT06160414","A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants",[86],"2024-02-05","2023-04-12",[15],[3076,3062,3077],"Metformin","ALXN2080",{"nctId":3079,"briefTitle":3080,"status":103,"phases":3081,"primaryCompletion":940,"completion":940,"start":3082,"enrollment":9,"conditions":3083,"interventions":3084},"NCT06071442","Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel\u002FEthinyl Estradiol-containing Oral Contraceptives, and Carbamazepine",[86],"2024-01-17",[1432],[3085,3062,3076,3086,3087],"Vemircopan","Levonorgestrel \u002F Ethinyl Estradiol","Carbamazepine",{"nctId":3089,"briefTitle":3090,"status":103,"phases":3091,"primaryCompletion":3092,"completion":3093,"start":3094,"enrollment":345,"conditions":3095,"interventions":3096},"NCT05708573","Potential Drug Interaction Between ALXN2040 and Rosuvastatin",[86],"2023-03-23","2023-04-05","2023-02-01",[1432],[3062,3097],"ALXN2040",{"trials":3099,"activeCount":97},[],{"trials":3101,"activeCount":97},[],{"trials":3103,"activeCount":97},[],{"trials":3105,"activeCount":97},[],{"intervention":3077,"totalTrials":756,"cells":3107},{"EARLY_PHASE1":3108,"PHASE1":3110,"PHASE2":3136,"PHASE3":3138,"PHASE4":3140,"NA":3142},{"trials":3109,"activeCount":97},[],{"trials":3111,"activeCount":97},[3112,3116,3126],{"nctId":3069,"briefTitle":3070,"status":103,"phases":3113,"primaryCompletion":3072,"completion":3072,"start":3073,"enrollment":345,"conditions":3114,"interventions":3115},[86],[15],[3076,3062,3077],{"nctId":3117,"briefTitle":3118,"status":103,"phases":3119,"primaryCompletion":3120,"completion":3121,"start":3122,"enrollment":9,"conditions":3123,"interventions":3124},"NCT06173596","A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults",[86],"2024-04-30","2024-05-16","2024-01-10",[15],[3077,3125,2039,3087],"Itraconazole",{"nctId":3127,"briefTitle":3128,"status":103,"phases":3129,"primaryCompletion":3130,"completion":3131,"start":3132,"enrollment":3133,"conditions":3134,"interventions":3135},"NCT05428696","Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants",[86],"2023-04-24","2023-05-26","2022-09-12",90,[15],[3077],{"trials":3137,"activeCount":97},[],{"trials":3139,"activeCount":97},[],{"trials":3141,"activeCount":97},[],{"trials":3143,"activeCount":97},[],{"intervention":3145,"totalTrials":405,"cells":3146},"ALXN1007",{"EARLY_PHASE1":3147,"PHASE1":3149,"PHASE2":3168,"PHASE3":3170,"PHASE4":3172,"NA":3174},{"trials":3148,"activeCount":97},[],{"trials":3150,"activeCount":97},[3151,3160],{"nctId":3152,"briefTitle":3153,"status":103,"phases":3154,"primaryCompletion":3155,"completion":1076,"start":3156,"enrollment":3157,"conditions":3158,"interventions":3159},"NCT01454986","Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects",[86],"2013-08","2011-11",64,[15],[3145],{"nctId":3161,"briefTitle":3162,"status":103,"phases":3163,"primaryCompletion":1086,"completion":1171,"start":3164,"enrollment":22,"conditions":3165,"interventions":3167},"NCT01883544","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects",[86],"2013-06",[3166],"Healthy Subjects",[3145],{"trials":3169,"activeCount":97},[],{"trials":3171,"activeCount":97},[],{"trials":3173,"activeCount":97},[],{"trials":3175,"activeCount":97},[],{"intervention":110,"totalTrials":405,"cells":3177},{"EARLY_PHASE1":3178,"PHASE1":3180,"PHASE2":3197,"PHASE3":3199,"PHASE4":3201,"NA":3203},{"trials":3179,"activeCount":97},[],{"trials":3181,"activeCount":97},[3182,3193],{"nctId":3183,"briefTitle":3184,"status":103,"phases":3185,"primaryCompletion":3186,"completion":3186,"start":3187,"enrollment":3188,"conditions":3189,"interventions":3190},"NCT04920370","Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects",[86],"2021-11-16","2019-09-04",97,[15],[3191,3192,110],"ALXN1720 SC","ALXN1720 IV",{"nctId":101,"briefTitle":102,"status":103,"phases":3194,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":3195,"interventions":3196},[86],[15],[75,110],{"trials":3198,"activeCount":97},[],{"trials":3200,"activeCount":97},[],{"trials":3202,"activeCount":97},[],{"trials":3204,"activeCount":97},[],{"intervention":557,"totalTrials":405,"cells":3206},{"EARLY_PHASE1":3207,"PHASE1":3209,"PHASE2":3225,"PHASE3":3227,"PHASE4":3229,"NA":3231},{"trials":3208,"activeCount":97},[],{"trials":3210,"activeCount":97},[3211,3221],{"nctId":3212,"briefTitle":3213,"status":103,"phases":3214,"primaryCompletion":3215,"completion":3215,"start":3216,"enrollment":254,"conditions":3217,"interventions":3218},"NCT04709081","A Drug Interaction Study of ACH-0145228",[86],"2020-04-16","2019-12-22",[15],[3219,557,3220,3125],"ACH-0145228","Digoxin",{"nctId":548,"briefTitle":549,"status":103,"phases":3222,"primaryCompletion":551,"completion":552,"start":553,"enrollment":554,"conditions":3223,"interventions":3224},[86],[15],[481,557,558,559],{"trials":3226,"activeCount":97},[],{"trials":3228,"activeCount":97},[],{"trials":3230,"activeCount":97},[],{"trials":3232,"activeCount":97},[],{"intervention":3125,"totalTrials":405,"cells":3234},{"EARLY_PHASE1":3235,"PHASE1":3237,"PHASE2":3247,"PHASE3":3249,"PHASE4":3251,"NA":3253},{"trials":3236,"activeCount":97},[],{"trials":3238,"activeCount":97},[3239,3243],{"nctId":3212,"briefTitle":3213,"status":103,"phases":3240,"primaryCompletion":3215,"completion":3215,"start":3216,"enrollment":254,"conditions":3241,"interventions":3242},[86],[15],[3219,557,3220,3125],{"nctId":3117,"briefTitle":3118,"status":103,"phases":3244,"primaryCompletion":3120,"completion":3121,"start":3122,"enrollment":9,"conditions":3245,"interventions":3246},[86],[15],[3077,3125,2039,3087],{"trials":3248,"activeCount":97},[],{"trials":3250,"activeCount":97},[],{"trials":3252,"activeCount":97},[],{"trials":3254,"activeCount":97},[],{"intervention":3076,"totalTrials":405,"cells":3256},{"EARLY_PHASE1":3257,"PHASE1":3259,"PHASE2":3269,"PHASE3":3271,"PHASE4":3273,"NA":3275},{"trials":3258,"activeCount":97},[],{"trials":3260,"activeCount":97},[3261,3265],{"nctId":3069,"briefTitle":3070,"status":103,"phases":3262,"primaryCompletion":3072,"completion":3072,"start":3073,"enrollment":345,"conditions":3263,"interventions":3264},[86],[15],[3076,3062,3077],{"nctId":3079,"briefTitle":3080,"status":103,"phases":3266,"primaryCompletion":940,"completion":940,"start":3082,"enrollment":9,"conditions":3267,"interventions":3268},[86],[1432],[3085,3062,3076,3086,3087],{"trials":3270,"activeCount":97},[],{"trials":3272,"activeCount":97},[],{"trials":3274,"activeCount":97},[],{"trials":3276,"activeCount":97},[],{"intervention":3087,"totalTrials":405,"cells":3278},{"EARLY_PHASE1":3279,"PHASE1":3281,"PHASE2":3291,"PHASE3":3293,"PHASE4":3295,"NA":3297},{"trials":3280,"activeCount":97},[],{"trials":3282,"activeCount":97},[3283,3287],{"nctId":3079,"briefTitle":3080,"status":103,"phases":3284,"primaryCompletion":940,"completion":940,"start":3082,"enrollment":9,"conditions":3285,"interventions":3286},[86],[1432],[3085,3062,3076,3086,3087],{"nctId":3117,"briefTitle":3118,"status":103,"phases":3288,"primaryCompletion":3120,"completion":3121,"start":3122,"enrollment":9,"conditions":3289,"interventions":3290},[86],[15],[3077,3125,2039,3087],{"trials":3292,"activeCount":97},[],{"trials":3294,"activeCount":97},[],{"trials":3296,"activeCount":97},[],{"trials":3298,"activeCount":97},[],{"intervention":2039,"totalTrials":405,"cells":3300},{"EARLY_PHASE1":3301,"PHASE1":3303,"PHASE2":3313,"PHASE3":3315,"PHASE4":3317,"NA":3319},{"trials":3302,"activeCount":97},[],{"trials":3304,"activeCount":97},[3305,3309],{"nctId":3117,"briefTitle":3118,"status":103,"phases":3306,"primaryCompletion":3120,"completion":3121,"start":3122,"enrollment":9,"conditions":3307,"interventions":3308},[86],[15],[3077,3125,2039,3087],{"nctId":2033,"briefTitle":2034,"status":103,"phases":3310,"primaryCompletion":440,"completion":440,"start":2036,"enrollment":22,"conditions":3311,"interventions":3312},[86],[15],[1999,2039,2040],{"trials":3314,"activeCount":97},[],{"trials":3316,"activeCount":97},[],{"trials":3318,"activeCount":97},[],{"trials":3320,"activeCount":97},[],{"intervention":577,"totalTrials":405,"cells":3322},{"EARLY_PHASE1":3323,"PHASE1":3325,"PHASE2":3335,"PHASE3":3337,"PHASE4":3339,"NA":3341},{"trials":3324,"activeCount":97},[],{"trials":3326,"activeCount":97},[3327,3331],{"nctId":2060,"briefTitle":2061,"status":103,"phases":3328,"primaryCompletion":2019,"completion":2019,"start":2063,"enrollment":2064,"conditions":3329,"interventions":3330},[86],[15],[1999,577,578,2067],{"nctId":569,"briefTitle":570,"status":103,"phases":3332,"primaryCompletion":572,"completion":572,"start":573,"enrollment":574,"conditions":3333,"interventions":3334},[86],[15],[481,577,578,579,580,581],{"trials":3336,"activeCount":97},[],{"trials":3338,"activeCount":97},[],{"trials":3340,"activeCount":97},[],{"trials":3342,"activeCount":97},[],{"intervention":578,"totalTrials":405,"cells":3344},{"EARLY_PHASE1":3345,"PHASE1":3347,"PHASE2":3357,"PHASE3":3359,"PHASE4":3361,"NA":3363},{"trials":3346,"activeCount":97},[],{"trials":3348,"activeCount":97},[3349,3353],{"nctId":2060,"briefTitle":2061,"status":103,"phases":3350,"primaryCompletion":2019,"completion":2019,"start":2063,"enrollment":2064,"conditions":3351,"interventions":3352},[86],[15],[1999,577,578,2067],{"nctId":569,"briefTitle":570,"status":103,"phases":3354,"primaryCompletion":572,"completion":572,"start":573,"enrollment":574,"conditions":3355,"interventions":3356},[86],[15],[481,577,578,579,580,581],{"trials":3358,"activeCount":97},[],{"trials":3360,"activeCount":97},[],{"trials":3362,"activeCount":97},[],{"trials":3364,"activeCount":97},[],{"intervention":3366,"totalTrials":428,"cells":3367},"ALXN2050 MR Prototype",{"EARLY_PHASE1":3368,"PHASE1":3370,"PHASE2":3382,"PHASE3":3384,"PHASE4":3386,"NA":3388},{"trials":3369,"activeCount":97},[],{"trials":3371,"activeCount":97},[3372],{"nctId":3373,"briefTitle":3374,"status":103,"phases":3375,"primaryCompletion":3376,"completion":3376,"start":3377,"enrollment":674,"conditions":3378,"interventions":3379},"NCT05780645","A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants",[86],"2024-02-26","2023-03-15",[1432],[3366,3380,3381],"ALXN2050 Immediate Release (IR)","ALXN2050 MR Prototype Mini-Tablet",{"trials":3383,"activeCount":97},[],{"trials":3385,"activeCount":97},[],{"trials":3387,"activeCount":97},[],{"trials":3389,"activeCount":97},[],{"intervention":3380,"totalTrials":428,"cells":3391},{"EARLY_PHASE1":3392,"PHASE1":3394,"PHASE2":3400,"PHASE3":3402,"PHASE4":3404,"NA":3406},{"trials":3393,"activeCount":97},[],{"trials":3395,"activeCount":97},[3396],{"nctId":3373,"briefTitle":3374,"status":103,"phases":3397,"primaryCompletion":3376,"completion":3376,"start":3377,"enrollment":674,"conditions":3398,"interventions":3399},[86],[1432],[3366,3380,3381],{"trials":3401,"activeCount":97},[],{"trials":3403,"activeCount":97},[],{"trials":3405,"activeCount":97},[],{"trials":3407,"activeCount":97},[],{"intervention":3381,"totalTrials":428,"cells":3409},{"EARLY_PHASE1":3410,"PHASE1":3412,"PHASE2":3418,"PHASE3":3420,"PHASE4":3422,"NA":3424},{"trials":3411,"activeCount":97},[],{"trials":3413,"activeCount":97},[3414],{"nctId":3373,"briefTitle":3374,"status":103,"phases":3415,"primaryCompletion":3376,"completion":3376,"start":3377,"enrollment":674,"conditions":3416,"interventions":3417},[86],[1432],[3366,3380,3381],{"trials":3419,"activeCount":97},[],{"trials":3421,"activeCount":97},[],{"trials":3423,"activeCount":97},[],{"trials":3425,"activeCount":97},[],{"intervention":3039,"totalTrials":428,"cells":3427},{"EARLY_PHASE1":3428,"PHASE1":3430,"PHASE2":3436,"PHASE3":3438,"PHASE4":3440,"NA":3442},{"trials":3429,"activeCount":97},[],{"trials":3431,"activeCount":97},[3432],{"nctId":3032,"briefTitle":3033,"status":103,"phases":3433,"primaryCompletion":3035,"completion":3035,"start":3036,"enrollment":19,"conditions":3434,"interventions":3435},[86],[15],[3039,3040,581],{"trials":3437,"activeCount":97},[],{"trials":3439,"activeCount":97},[],{"trials":3441,"activeCount":97},[],{"trials":3443,"activeCount":97},[],{"intervention":3040,"totalTrials":428,"cells":3445},{"EARLY_PHASE1":3446,"PHASE1":3448,"PHASE2":3454,"PHASE3":3456,"PHASE4":3458,"NA":3460},{"trials":3447,"activeCount":97},[],{"trials":3449,"activeCount":97},[3450],{"nctId":3032,"briefTitle":3033,"status":103,"phases":3451,"primaryCompletion":3035,"completion":3035,"start":3036,"enrollment":19,"conditions":3452,"interventions":3453},[86],[15],[3039,3040,581],{"trials":3455,"activeCount":97},[],{"trials":3457,"activeCount":97},[],{"trials":3459,"activeCount":97},[],{"trials":3461,"activeCount":97},[],{"intervention":3463,"totalTrials":428,"cells":3464},"Danicopan Modified Release Prototype 1",{"EARLY_PHASE1":3465,"PHASE1":3467,"PHASE2":3479,"PHASE3":3481,"PHASE4":3483,"NA":3485},{"trials":3466,"activeCount":97},[],{"trials":3468,"activeCount":97},[3469],{"nctId":3470,"briefTitle":3471,"status":103,"phases":3472,"primaryCompletion":3473,"completion":3473,"start":3474,"enrollment":826,"conditions":3475,"interventions":3476},"NCT03384186","A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants",[86],"2018-03-21","2017-12-01",[15],[3463,3477,3478],"Danicopan Modified Release Prototype 2","Danicopan Modified Release Prototype 3",{"trials":3480,"activeCount":97},[],{"trials":3482,"activeCount":97},[],{"trials":3484,"activeCount":97},[],{"trials":3486,"activeCount":97},[],{"intervention":3477,"totalTrials":428,"cells":3488},{"EARLY_PHASE1":3489,"PHASE1":3491,"PHASE2":3497,"PHASE3":3499,"PHASE4":3501,"NA":3503},{"trials":3490,"activeCount":97},[],{"trials":3492,"activeCount":97},[3493],{"nctId":3470,"briefTitle":3471,"status":103,"phases":3494,"primaryCompletion":3473,"completion":3473,"start":3474,"enrollment":826,"conditions":3495,"interventions":3496},[86],[15],[3463,3477,3478],{"trials":3498,"activeCount":97},[],{"trials":3500,"activeCount":97},[],{"trials":3502,"activeCount":97},[],{"trials":3504,"activeCount":97},[],{"intervention":3478,"totalTrials":428,"cells":3506},{"EARLY_PHASE1":3507,"PHASE1":3509,"PHASE2":3515,"PHASE3":3517,"PHASE4":3519,"NA":3521},{"trials":3508,"activeCount":97},[],{"trials":3510,"activeCount":97},[3511],{"nctId":3470,"briefTitle":3471,"status":103,"phases":3512,"primaryCompletion":3473,"completion":3473,"start":3474,"enrollment":826,"conditions":3513,"interventions":3514},[86],[15],[3463,3477,3478],{"trials":3516,"activeCount":97},[],{"trials":3518,"activeCount":97},[],{"trials":3520,"activeCount":97},[],{"trials":3522,"activeCount":97},[],{"intervention":3524,"totalTrials":428,"cells":3525},"Danicopan -",{"EARLY_PHASE1":3526,"PHASE1":3528,"PHASE2":3540,"PHASE3":3542,"PHASE4":3544,"NA":3546},{"trials":3527,"activeCount":97},[],{"trials":3529,"activeCount":97},[3530],{"nctId":3531,"briefTitle":3532,"status":103,"phases":3533,"primaryCompletion":3534,"completion":3534,"start":3535,"enrollment":133,"conditions":3536,"interventions":3537},"NCT04940559","Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants",[86],"2016-10-05","2016-08-02",[15],[3524,3538,3539],"Danicopan - Softgel","Danicopan - LFC",{"trials":3541,"activeCount":97},[],{"trials":3543,"activeCount":97},[],{"trials":3545,"activeCount":97},[],{"trials":3547,"activeCount":97},[],{"intervention":3538,"totalTrials":428,"cells":3549},{"EARLY_PHASE1":3550,"PHASE1":3552,"PHASE2":3558,"PHASE3":3560,"PHASE4":3562,"NA":3564},{"trials":3551,"activeCount":97},[],{"trials":3553,"activeCount":97},[3554],{"nctId":3531,"briefTitle":3532,"status":103,"phases":3555,"primaryCompletion":3534,"completion":3534,"start":3535,"enrollment":133,"conditions":3556,"interventions":3557},[86],[15],[3524,3538,3539],{"trials":3559,"activeCount":97},[],{"trials":3561,"activeCount":97},[],{"trials":3563,"activeCount":97},[],{"trials":3565,"activeCount":97},[],{"intervention":3539,"totalTrials":428,"cells":3567},{"EARLY_PHASE1":3568,"PHASE1":3570,"PHASE2":3576,"PHASE3":3578,"PHASE4":3580,"NA":3582},{"trials":3569,"activeCount":97},[],{"trials":3571,"activeCount":97},[3572],{"nctId":3531,"briefTitle":3532,"status":103,"phases":3573,"primaryCompletion":3534,"completion":3534,"start":3535,"enrollment":133,"conditions":3574,"interventions":3575},[86],[15],[3524,3538,3539],{"trials":3577,"activeCount":97},[],{"trials":3579,"activeCount":97},[],{"trials":3581,"activeCount":97},[],{"trials":3583,"activeCount":97},[],{"intervention":3191,"totalTrials":428,"cells":3585},{"EARLY_PHASE1":3586,"PHASE1":3588,"PHASE2":3594,"PHASE3":3596,"PHASE4":3598,"NA":3600},{"trials":3587,"activeCount":97},[],{"trials":3589,"activeCount":97},[3590],{"nctId":3183,"briefTitle":3184,"status":103,"phases":3591,"primaryCompletion":3186,"completion":3186,"start":3187,"enrollment":3188,"conditions":3592,"interventions":3593},[86],[15],[3191,3192,110],{"trials":3595,"activeCount":97},[],{"trials":3597,"activeCount":97},[],{"trials":3599,"activeCount":97},[],{"trials":3601,"activeCount":97},[],{"intervention":3192,"totalTrials":428,"cells":3603},{"EARLY_PHASE1":3604,"PHASE1":3606,"PHASE2":3612,"PHASE3":3614,"PHASE4":3616,"NA":3618},{"trials":3605,"activeCount":97},[],{"trials":3607,"activeCount":97},[3608],{"nctId":3183,"briefTitle":3184,"status":103,"phases":3609,"primaryCompletion":3186,"completion":3186,"start":3187,"enrollment":3188,"conditions":3610,"interventions":3611},[86],[15],[3191,3192,110],{"trials":3613,"activeCount":97},[],{"trials":3615,"activeCount":97},[],{"trials":3617,"activeCount":97},[],{"trials":3619,"activeCount":97},[],{"intervention":3621,"totalTrials":428,"cells":3622},"Betrixaban",{"EARLY_PHASE1":3623,"PHASE1":3625,"PHASE2":3636,"PHASE3":3638,"PHASE4":3640,"NA":3642},{"trials":3624,"activeCount":97},[],{"trials":3626,"activeCount":97},[3627],{"nctId":3628,"briefTitle":3629,"status":116,"phases":3630,"primaryCompletion":3631,"completion":3631,"start":3632,"enrollment":206,"conditions":3633,"interventions":3635},"NCT03346083","Study Evaluating Betrixaban in Pediatric Participants",[86],"2019-10-08","2018-07-13",[3634],"VTE Prophylaxis",[3621],{"trials":3637,"activeCount":97},[],{"trials":3639,"activeCount":97},[],{"trials":3641,"activeCount":97},[],{"trials":3643,"activeCount":97},[],{"intervention":3645,"totalTrials":428,"cells":3646},"[14C]-ALXN2050",{"EARLY_PHASE1":3647,"PHASE1":3649,"PHASE2":3658,"PHASE3":3660,"PHASE4":3662,"NA":3664},{"trials":3648,"activeCount":97},[],{"trials":3650,"activeCount":97},[3651],{"nctId":3652,"briefTitle":3653,"status":103,"phases":3654,"primaryCompletion":599,"completion":599,"start":3655,"enrollment":525,"conditions":3656,"interventions":3657},"NCT04609670","Study of Radiolabeled ALXN2050 in Healthy Adult Males",[86],"2021-04-12",[15],[3645],{"trials":3659,"activeCount":97},[],{"trials":3661,"activeCount":97},[],{"trials":3663,"activeCount":97},[],{"trials":3665,"activeCount":97},[],{"intervention":507,"totalTrials":428,"cells":3667},{"EARLY_PHASE1":3668,"PHASE1":3670,"PHASE2":3676,"PHASE3":3678,"PHASE4":3680,"NA":3682},{"trials":3669,"activeCount":97},[],{"trials":3671,"activeCount":97},[3672],{"nctId":498,"briefTitle":499,"status":103,"phases":3673,"primaryCompletion":501,"completion":502,"start":503,"enrollment":504,"conditions":3674,"interventions":3675},[86],[15],[481,507,508,509],{"trials":3677,"activeCount":97},[],{"trials":3679,"activeCount":97},[],{"trials":3681,"activeCount":97},[],{"trials":3683,"activeCount":97},[],{"intervention":508,"totalTrials":428,"cells":3685},{"EARLY_PHASE1":3686,"PHASE1":3688,"PHASE2":3694,"PHASE3":3696,"PHASE4":3698,"NA":3700},{"trials":3687,"activeCount":97},[],{"trials":3689,"activeCount":97},[3690],{"nctId":498,"briefTitle":499,"status":103,"phases":3691,"primaryCompletion":501,"completion":502,"start":503,"enrollment":504,"conditions":3692,"interventions":3693},[86],[15],[481,507,508,509],{"trials":3695,"activeCount":97},[],{"trials":3697,"activeCount":97},[],{"trials":3699,"activeCount":97},[],{"trials":3701,"activeCount":97},[],{"intervention":509,"totalTrials":428,"cells":3703},{"EARLY_PHASE1":3704,"PHASE1":3706,"PHASE2":3712,"PHASE3":3714,"PHASE4":3716,"NA":3718},{"trials":3705,"activeCount":97},[],{"trials":3707,"activeCount":97},[3708],{"nctId":498,"briefTitle":499,"status":103,"phases":3709,"primaryCompletion":501,"completion":502,"start":503,"enrollment":504,"conditions":3710,"interventions":3711},[86],[15],[481,507,508,509],{"trials":3713,"activeCount":97},[],{"trials":3715,"activeCount":97},[],{"trials":3717,"activeCount":97},[],{"trials":3719,"activeCount":97},[],{"intervention":3721,"totalTrials":428,"cells":3722},"Gefurulimab PFS-SD",{"EARLY_PHASE1":3723,"PHASE1":3725,"PHASE2":3737,"PHASE3":3739,"PHASE4":3741,"NA":3743},{"trials":3724,"activeCount":97},[],{"trials":3726,"activeCount":97},[3727],{"nctId":3728,"briefTitle":3729,"status":103,"phases":3730,"primaryCompletion":3731,"completion":3732,"start":3733,"enrollment":336,"conditions":3734,"interventions":3735},"NCT06208488","A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants",[86],"2024-09-17","2024-09-28","2023-11-22",[1566],[3721,3736],"Gefurulimab AI",{"trials":3738,"activeCount":97},[],{"trials":3740,"activeCount":97},[],{"trials":3742,"activeCount":97},[],{"trials":3744,"activeCount":97},[],{"intervention":3736,"totalTrials":428,"cells":3746},{"EARLY_PHASE1":3747,"PHASE1":3749,"PHASE2":3755,"PHASE3":3757,"PHASE4":3759,"NA":3761},{"trials":3748,"activeCount":97},[],{"trials":3750,"activeCount":97},[3751],{"nctId":3728,"briefTitle":3729,"status":103,"phases":3752,"primaryCompletion":3731,"completion":3732,"start":3733,"enrollment":336,"conditions":3753,"interventions":3754},[86],[1566],[3721,3736],{"trials":3756,"activeCount":97},[],{"trials":3758,"activeCount":97},[],{"trials":3760,"activeCount":97},[],{"trials":3762,"activeCount":97},[],{"intervention":3764,"totalTrials":428,"cells":3765},"Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4",{"EARLY_PHASE1":3766,"PHASE1":3768,"PHASE2":3778,"PHASE3":3780,"PHASE4":3782,"NA":3784},{"trials":3767,"activeCount":97},[],{"trials":3769,"activeCount":97},[3770],{"nctId":3771,"briefTitle":3772,"status":103,"phases":3773,"primaryCompletion":3774,"completion":3774,"start":3775,"enrollment":739,"conditions":3776,"interventions":3777},"NCT02245867","Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis",[86],"2017-07-13","2014-10-30",[777],[3764],{"trials":3779,"activeCount":97},[],{"trials":3781,"activeCount":97},[],{"trials":3783,"activeCount":97},[],{"trials":3785,"activeCount":97},[],{"intervention":3219,"totalTrials":428,"cells":3787},{"EARLY_PHASE1":3788,"PHASE1":3790,"PHASE2":3796,"PHASE3":3798,"PHASE4":3800,"NA":3802},{"trials":3789,"activeCount":97},[],{"trials":3791,"activeCount":97},[3792],{"nctId":3212,"briefTitle":3213,"status":103,"phases":3793,"primaryCompletion":3215,"completion":3215,"start":3216,"enrollment":254,"conditions":3794,"interventions":3795},[86],[15],[3219,557,3220,3125],{"trials":3797,"activeCount":97},[],{"trials":3799,"activeCount":97},[],{"trials":3801,"activeCount":97},[],{"trials":3803,"activeCount":97},[],{"intervention":3220,"totalTrials":428,"cells":3805},{"EARLY_PHASE1":3806,"PHASE1":3808,"PHASE2":3814,"PHASE3":3816,"PHASE4":3818,"NA":3820},{"trials":3807,"activeCount":97},[],{"trials":3809,"activeCount":97},[3810],{"nctId":3212,"briefTitle":3213,"status":103,"phases":3811,"primaryCompletion":3215,"completion":3215,"start":3216,"enrollment":254,"conditions":3812,"interventions":3813},[86],[15],[3219,557,3220,3125],{"trials":3815,"activeCount":97},[],{"trials":3817,"activeCount":97},[],{"trials":3819,"activeCount":97},[],{"trials":3821,"activeCount":97},[],{"intervention":3823,"totalTrials":428,"cells":3824},"ALXN1910",{"EARLY_PHASE1":3825,"PHASE1":3827,"PHASE2":3837,"PHASE3":3839,"PHASE4":3841,"NA":3843},{"trials":3826,"activeCount":97},[],{"trials":3828,"activeCount":97},[3829],{"nctId":3830,"briefTitle":3831,"status":103,"phases":3832,"primaryCompletion":3833,"completion":3833,"start":3834,"enrollment":1394,"conditions":3835,"interventions":3836},"NCT05307978","Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants",[86],"2023-02-07","2022-04-12",[15],[3823],{"trials":3838,"activeCount":97},[],{"trials":3840,"activeCount":97},[],{"trials":3842,"activeCount":97},[],{"trials":3844,"activeCount":97},[],{"intervention":3846,"totalTrials":428,"cells":3847},"ALXN1102",{"EARLY_PHASE1":3848,"PHASE1":3850,"PHASE2":3861,"PHASE3":3863,"PHASE4":3865,"NA":3867},{"trials":3849,"activeCount":97},[],{"trials":3851,"activeCount":97},[3852],{"nctId":3853,"briefTitle":3854,"status":116,"phases":3855,"primaryCompletion":3856,"completion":3856,"start":3857,"enrollment":28,"conditions":3858,"interventions":3859},"NCT01335165","Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)",[86],"2014-03","2011-04",[265],[3846,3860],"ALXN1103",{"trials":3862,"activeCount":97},[],{"trials":3864,"activeCount":97},[],{"trials":3866,"activeCount":97},[],{"trials":3868,"activeCount":97},[],{"intervention":3860,"totalTrials":428,"cells":3870},{"EARLY_PHASE1":3871,"PHASE1":3873,"PHASE2":3879,"PHASE3":3881,"PHASE4":3883,"NA":3885},{"trials":3872,"activeCount":97},[],{"trials":3874,"activeCount":97},[3875],{"nctId":3853,"briefTitle":3854,"status":116,"phases":3876,"primaryCompletion":3856,"completion":3856,"start":3857,"enrollment":28,"conditions":3877,"interventions":3878},[86],[265],[3846,3860],{"trials":3880,"activeCount":97},[],{"trials":3882,"activeCount":97},[],{"trials":3884,"activeCount":97},[],{"trials":3886,"activeCount":97},[],{"intervention":3888,"totalTrials":428,"cells":3889},"Danicopan: Powder-In-Capsule 1",{"EARLY_PHASE1":3890,"PHASE1":3892,"PHASE2":3903,"PHASE3":3905,"PHASE4":3907,"NA":3909},{"trials":3891,"activeCount":97},[],{"trials":3893,"activeCount":97},[3894],{"nctId":3895,"briefTitle":3896,"status":103,"phases":3897,"primaryCompletion":157,"completion":157,"start":3898,"enrollment":12,"conditions":3899,"interventions":3900},"NCT04609696","Study of the Metabolism of Danicopan in Healthy Adults",[86],"2020-10-20",[15],[3888,3901,3902],"Danicopan: Powder-In-Capsule 2","Danicopan:",{"trials":3904,"activeCount":97},[],{"trials":3906,"activeCount":97},[],{"trials":3908,"activeCount":97},[],{"trials":3910,"activeCount":97},[],{"intervention":3901,"totalTrials":428,"cells":3912},{"EARLY_PHASE1":3913,"PHASE1":3915,"PHASE2":3921,"PHASE3":3923,"PHASE4":3925,"NA":3927},{"trials":3914,"activeCount":97},[],{"trials":3916,"activeCount":97},[3917],{"nctId":3895,"briefTitle":3896,"status":103,"phases":3918,"primaryCompletion":157,"completion":157,"start":3898,"enrollment":12,"conditions":3919,"interventions":3920},[86],[15],[3888,3901,3902],{"trials":3922,"activeCount":97},[],{"trials":3924,"activeCount":97},[],{"trials":3926,"activeCount":97},[],{"trials":3928,"activeCount":97},[],{"intervention":3902,"totalTrials":428,"cells":3930},{"EARLY_PHASE1":3931,"PHASE1":3933,"PHASE2":3939,"PHASE3":3941,"PHASE4":3943,"NA":3945},{"trials":3932,"activeCount":97},[],{"trials":3934,"activeCount":97},[3935],{"nctId":3895,"briefTitle":3896,"status":103,"phases":3936,"primaryCompletion":157,"completion":157,"start":3898,"enrollment":12,"conditions":3937,"interventions":3938},[86],[15],[3888,3901,3902],{"trials":3940,"activeCount":97},[],{"trials":3942,"activeCount":97},[],{"trials":3944,"activeCount":97},[],{"trials":3946,"activeCount":97},[],{"intervention":3085,"totalTrials":428,"cells":3948},{"EARLY_PHASE1":3949,"PHASE1":3951,"PHASE2":3957,"PHASE3":3959,"PHASE4":3961,"NA":3963},{"trials":3950,"activeCount":97},[],{"trials":3952,"activeCount":97},[3953],{"nctId":3079,"briefTitle":3080,"status":103,"phases":3954,"primaryCompletion":940,"completion":940,"start":3082,"enrollment":9,"conditions":3955,"interventions":3956},[86],[1432],[3085,3062,3076,3086,3087],{"trials":3958,"activeCount":97},[],{"trials":3960,"activeCount":97},[],{"trials":3962,"activeCount":97},[],{"trials":3964,"activeCount":97},[],{"intervention":3086,"totalTrials":428,"cells":3966},{"EARLY_PHASE1":3967,"PHASE1":3969,"PHASE2":3975,"PHASE3":3977,"PHASE4":3979,"NA":3981},{"trials":3968,"activeCount":97},[],{"trials":3970,"activeCount":97},[3971],{"nctId":3079,"briefTitle":3080,"status":103,"phases":3972,"primaryCompletion":940,"completion":940,"start":3082,"enrollment":9,"conditions":3973,"interventions":3974},[86],[1432],[3085,3062,3076,3086,3087],{"trials":3976,"activeCount":97},[],{"trials":3978,"activeCount":97},[],{"trials":3980,"activeCount":97},[],{"trials":3982,"activeCount":97},[],{"intervention":3984,"totalTrials":428,"cells":3985},"Celecoxib",{"EARLY_PHASE1":3986,"PHASE1":3988,"PHASE2":3998,"PHASE3":4000,"PHASE4":4002,"NA":4004},{"trials":3987,"activeCount":97},[],{"trials":3989,"activeCount":97},[3990],{"nctId":3991,"briefTitle":3992,"status":103,"phases":3993,"primaryCompletion":794,"completion":794,"start":3994,"enrollment":3995,"conditions":3996,"interventions":3997},"NCT04526197","Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.",[86],"2020-07-07",36,[27],[1869,3984],{"trials":3999,"activeCount":97},[],{"trials":4001,"activeCount":97},[],{"trials":4003,"activeCount":97},[],{"trials":4005,"activeCount":97},[],{"intervention":4007,"totalTrials":428,"cells":4008},"ACH-0145228: Immediate Release",{"EARLY_PHASE1":4009,"PHASE1":4011,"PHASE2":4022,"PHASE3":4024,"PHASE4":4026,"NA":4028},{"trials":4010,"activeCount":97},[],{"trials":4012,"activeCount":97},[4013],{"nctId":4014,"briefTitle":4015,"status":103,"phases":4016,"primaryCompletion":4017,"completion":4017,"start":4018,"enrollment":2011,"conditions":4019,"interventions":4020},"NCT04551586","A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants",[86],"2020-10-19","2020-06-26",[15],[4007,4021],"ACH-0145228: Powder-in-capsule",{"trials":4023,"activeCount":97},[],{"trials":4025,"activeCount":97},[],{"trials":4027,"activeCount":97},[],{"trials":4029,"activeCount":97},[],{"intervention":4021,"totalTrials":428,"cells":4031},{"EARLY_PHASE1":4032,"PHASE1":4034,"PHASE2":4040,"PHASE3":4042,"PHASE4":4044,"NA":4046},{"trials":4033,"activeCount":97},[],{"trials":4035,"activeCount":97},[4036],{"nctId":4014,"briefTitle":4015,"status":103,"phases":4037,"primaryCompletion":4017,"completion":4017,"start":4018,"enrollment":2011,"conditions":4038,"interventions":4039},[86],[15],[4007,4021],{"trials":4041,"activeCount":97},[],{"trials":4043,"activeCount":97},[],{"trials":4045,"activeCount":97},[],{"trials":4047,"activeCount":97},[],{"intervention":3097,"totalTrials":428,"cells":4049},{"EARLY_PHASE1":4050,"PHASE1":4052,"PHASE2":4058,"PHASE3":4060,"PHASE4":4062,"NA":4064},{"trials":4051,"activeCount":97},[],{"trials":4053,"activeCount":97},[4054],{"nctId":3089,"briefTitle":3090,"status":103,"phases":4055,"primaryCompletion":3092,"completion":3093,"start":3094,"enrollment":345,"conditions":4056,"interventions":4057},[86],[1432],[3062,3097],{"trials":4059,"activeCount":97},[],{"trials":4061,"activeCount":97},[],{"trials":4063,"activeCount":97},[],{"trials":4065,"activeCount":97},[],{"intervention":4067,"totalTrials":428,"cells":4068},"Bupropion Hydrochloride",{"EARLY_PHASE1":4069,"PHASE1":4071,"PHASE2":4082,"PHASE3":4084,"PHASE4":4086,"NA":4088},{"trials":4070,"activeCount":97},[],{"trials":4072,"activeCount":97},[4073],{"nctId":4074,"briefTitle":4075,"status":103,"phases":4076,"primaryCompletion":4077,"completion":4077,"start":4078,"enrollment":4079,"conditions":4080,"interventions":4081},"NCT04526210","Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants",[86],"2021-05-28","2020-10-21",54,[27],[1869,4067],{"trials":4083,"activeCount":97},[],{"trials":4085,"activeCount":97},[],{"trials":4087,"activeCount":97},[],{"trials":4089,"activeCount":97},[],{"intervention":4091,"totalTrials":428,"cells":4092},"ALXN1210 SC",{"EARLY_PHASE1":4093,"PHASE1":4095,"PHASE2":4106,"PHASE3":4108,"PHASE4":4110,"NA":4112},{"trials":4094,"activeCount":97},[],{"trials":4096,"activeCount":97},[4097],{"nctId":4098,"briefTitle":4099,"status":103,"phases":4100,"primaryCompletion":2180,"completion":2180,"start":4101,"enrollment":4102,"conditions":4103,"interventions":4104},"NCT05288829","A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants",[86],"2016-08-19",42,[15],[4091,4105],"ALXN1210 IV",{"trials":4107,"activeCount":97},[],{"trials":4109,"activeCount":97},[],{"trials":4111,"activeCount":97},[],{"trials":4113,"activeCount":97},[],{"intervention":4105,"totalTrials":428,"cells":4115},{"EARLY_PHASE1":4116,"PHASE1":4118,"PHASE2":4124,"PHASE3":4126,"PHASE4":4128,"NA":4130},{"trials":4117,"activeCount":97},[],{"trials":4119,"activeCount":97},[4120],{"nctId":4098,"briefTitle":4099,"status":103,"phases":4121,"primaryCompletion":2180,"completion":2180,"start":4101,"enrollment":4102,"conditions":4122,"interventions":4123},[86],[15],[4091,4105],{"trials":4125,"activeCount":97},[],{"trials":4127,"activeCount":97},[],{"trials":4129,"activeCount":97},[],{"trials":4131,"activeCount":97},[],{"intervention":2040,"totalTrials":428,"cells":4133},{"EARLY_PHASE1":4134,"PHASE1":4136,"PHASE2":4142,"PHASE3":4144,"PHASE4":4146,"NA":4148},{"trials":4135,"activeCount":97},[],{"trials":4137,"activeCount":97},[4138],{"nctId":2033,"briefTitle":2034,"status":103,"phases":4139,"primaryCompletion":440,"completion":440,"start":2036,"enrollment":22,"conditions":4140,"interventions":4141},[86],[15],[1999,2039,2040],{"trials":4143,"activeCount":97},[],{"trials":4145,"activeCount":97},[],{"trials":4147,"activeCount":97},[],{"trials":4149,"activeCount":97},[],{"intervention":2347,"totalTrials":428,"cells":4151},{"EARLY_PHASE1":4152,"PHASE1":4154,"PHASE2":4160,"PHASE3":4162,"PHASE4":4164,"NA":4166},{"trials":4153,"activeCount":97},[],{"trials":4155,"activeCount":97},[4156],{"nctId":2339,"briefTitle":2340,"status":103,"phases":4157,"primaryCompletion":2342,"completion":2342,"start":2343,"enrollment":33,"conditions":4158,"interventions":4159},[86],[2345],[2347,2332],{"trials":4161,"activeCount":97},[],{"trials":4163,"activeCount":97},[],{"trials":4165,"activeCount":97},[],{"trials":4167,"activeCount":97},[],{"intervention":4169,"totalTrials":428,"cells":4170},"Treatment A",{"EARLY_PHASE1":4171,"PHASE1":4173,"PHASE2":4184,"PHASE3":4186,"PHASE4":4188,"NA":4190},{"trials":4172,"activeCount":97},[],{"trials":4174,"activeCount":97},[4175],{"nctId":4176,"briefTitle":4177,"status":103,"phases":4178,"primaryCompletion":624,"completion":624,"start":4179,"enrollment":4102,"conditions":4180,"interventions":4181},"NCT05578846","Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics",[86],"2022-10-13",[1566],[4169,4182,4183],"Treatment B","Treatment C",{"trials":4185,"activeCount":97},[],{"trials":4187,"activeCount":97},[],{"trials":4189,"activeCount":97},[],{"trials":4191,"activeCount":97},[],{"intervention":4182,"totalTrials":428,"cells":4193},{"EARLY_PHASE1":4194,"PHASE1":4196,"PHASE2":4202,"PHASE3":4204,"PHASE4":4206,"NA":4208},{"trials":4195,"activeCount":97},[],{"trials":4197,"activeCount":97},[4198],{"nctId":4176,"briefTitle":4177,"status":103,"phases":4199,"primaryCompletion":624,"completion":624,"start":4179,"enrollment":4102,"conditions":4200,"interventions":4201},[86],[1566],[4169,4182,4183],{"trials":4203,"activeCount":97},[],{"trials":4205,"activeCount":97},[],{"trials":4207,"activeCount":97},[],{"trials":4209,"activeCount":97},[],{"intervention":4183,"totalTrials":428,"cells":4211},{"EARLY_PHASE1":4212,"PHASE1":4214,"PHASE2":4220,"PHASE3":4222,"PHASE4":4224,"NA":4226},{"trials":4213,"activeCount":97},[],{"trials":4215,"activeCount":97},[4216],{"nctId":4176,"briefTitle":4177,"status":103,"phases":4217,"primaryCompletion":624,"completion":624,"start":4179,"enrollment":4102,"conditions":4218,"interventions":4219},[86],[1566],[4169,4182,4183],{"trials":4221,"activeCount":97},[],{"trials":4223,"activeCount":97},[],{"trials":4225,"activeCount":97},[],{"trials":4227,"activeCount":97},[],{"intervention":558,"totalTrials":428,"cells":4229},{"EARLY_PHASE1":4230,"PHASE1":4232,"PHASE2":4238,"PHASE3":4240,"PHASE4":4242,"NA":4244},{"trials":4231,"activeCount":97},[],{"trials":4233,"activeCount":97},[4234],{"nctId":548,"briefTitle":549,"status":103,"phases":4235,"primaryCompletion":551,"completion":552,"start":553,"enrollment":554,"conditions":4236,"interventions":4237},[86],[15],[481,557,558,559],{"trials":4239,"activeCount":97},[],{"trials":4241,"activeCount":97},[],{"trials":4243,"activeCount":97},[],{"trials":4245,"activeCount":97},[],{"intervention":559,"totalTrials":428,"cells":4247},{"EARLY_PHASE1":4248,"PHASE1":4250,"PHASE2":4256,"PHASE3":4258,"PHASE4":4260,"NA":4262},{"trials":4249,"activeCount":97},[],{"trials":4251,"activeCount":97},[4252],{"nctId":548,"briefTitle":549,"status":103,"phases":4253,"primaryCompletion":551,"completion":552,"start":553,"enrollment":554,"conditions":4254,"interventions":4255},[86],[15],[481,557,558,559],{"trials":4257,"activeCount":97},[],{"trials":4259,"activeCount":97},[],{"trials":4261,"activeCount":97},[],{"trials":4263,"activeCount":97},[],{"intervention":4265,"totalTrials":428,"cells":4266},"ALXN1820 SC",{"EARLY_PHASE1":4267,"PHASE1":4269,"PHASE2":4281,"PHASE3":4283,"PHASE4":4285,"NA":4287},{"trials":4268,"activeCount":97},[],{"trials":4270,"activeCount":97},[4271],{"nctId":4272,"briefTitle":4273,"status":103,"phases":4274,"primaryCompletion":4275,"completion":4275,"start":4276,"enrollment":4277,"conditions":4278,"interventions":4279},"NCT04631562","Study of ALXN1820 in Healthy Adult Participants",[86],"2022-09-01","2021-01-13",66,[15],[4265,4280],"ALXN1820 IV",{"trials":4282,"activeCount":97},[],{"trials":4284,"activeCount":97},[],{"trials":4286,"activeCount":97},[],{"trials":4288,"activeCount":97},[],{"intervention":4280,"totalTrials":428,"cells":4290},{"EARLY_PHASE1":4291,"PHASE1":4293,"PHASE2":4299,"PHASE3":4301,"PHASE4":4303,"NA":4305},{"trials":4292,"activeCount":97},[],{"trials":4294,"activeCount":97},[4295],{"nctId":4272,"briefTitle":4273,"status":103,"phases":4296,"primaryCompletion":4275,"completion":4275,"start":4276,"enrollment":4277,"conditions":4297,"interventions":4298},[86],[15],[4265,4280],{"trials":4300,"activeCount":97},[],{"trials":4302,"activeCount":97},[],{"trials":4304,"activeCount":97},[],{"trials":4306,"activeCount":97},[],{"intervention":2067,"totalTrials":428,"cells":4308},{"EARLY_PHASE1":4309,"PHASE1":4311,"PHASE2":4317,"PHASE3":4319,"PHASE4":4321,"NA":4323},{"trials":4310,"activeCount":97},[],{"trials":4312,"activeCount":97},[4313],{"nctId":2060,"briefTitle":2061,"status":103,"phases":4314,"primaryCompletion":2019,"completion":2019,"start":2063,"enrollment":2064,"conditions":4315,"interventions":4316},[86],[15],[1999,577,578,2067],{"trials":4318,"activeCount":97},[],{"trials":4320,"activeCount":97},[],{"trials":4322,"activeCount":97},[],{"trials":4324,"activeCount":97},[],{"intervention":4326,"totalTrials":428,"cells":4327},"[14C]-Danicopan",{"EARLY_PHASE1":4328,"PHASE1":4330,"PHASE2":4340,"PHASE3":4342,"PHASE4":4344,"NA":4346},{"trials":4329,"activeCount":97},[],{"trials":4331,"activeCount":97},[4332],{"nctId":4333,"briefTitle":4334,"status":103,"phases":4335,"primaryCompletion":4336,"completion":4336,"start":4337,"enrollment":33,"conditions":4338,"interventions":4339},"NCT04889391","Study of Radiolabeled Danicopan in Healthy Male Participants",[86],"2017-10-15","2017-09-14",[15],[4326],{"trials":4341,"activeCount":97},[],{"trials":4343,"activeCount":97},[],{"trials":4345,"activeCount":97},[],{"trials":4347,"activeCount":97},[],{"intervention":579,"totalTrials":428,"cells":4349},{"EARLY_PHASE1":4350,"PHASE1":4352,"PHASE2":4358,"PHASE3":4360,"PHASE4":4362,"NA":4364},{"trials":4351,"activeCount":97},[],{"trials":4353,"activeCount":97},[4354],{"nctId":569,"briefTitle":570,"status":103,"phases":4355,"primaryCompletion":572,"completion":572,"start":573,"enrollment":574,"conditions":4356,"interventions":4357},[86],[15],[481,577,578,579,580,581],{"trials":4359,"activeCount":97},[],{"trials":4361,"activeCount":97},[],{"trials":4363,"activeCount":97},[],{"trials":4365,"activeCount":97},[],{"intervention":580,"totalTrials":428,"cells":4367},{"EARLY_PHASE1":4368,"PHASE1":4370,"PHASE2":4376,"PHASE3":4378,"PHASE4":4380,"NA":4382},{"trials":4369,"activeCount":97},[],{"trials":4371,"activeCount":97},[4372],{"nctId":569,"briefTitle":570,"status":103,"phases":4373,"primaryCompletion":572,"completion":572,"start":573,"enrollment":574,"conditions":4374,"interventions":4375},[86],[15],[481,577,578,579,580,581],{"trials":4377,"activeCount":97},[],{"trials":4379,"activeCount":97},[],{"trials":4381,"activeCount":97},[],{"trials":4383,"activeCount":97},[],{"intervention":1869,"totalTrials":313,"cells":4385},{"EARLY_PHASE1":4386,"PHASE1":4388,"PHASE2":4439,"PHASE3":4457,"PHASE4":4467,"NA":4469},{"trials":4387,"activeCount":97},[],{"trials":4389,"activeCount":97},[4390,4394,4398,4402,4406,4415,4423,4431],{"nctId":3002,"briefTitle":3003,"status":103,"phases":4391,"primaryCompletion":3005,"completion":3005,"start":3006,"enrollment":1271,"conditions":4392,"interventions":4393},[86],[15],[1869,537],{"nctId":3991,"briefTitle":3992,"status":103,"phases":4395,"primaryCompletion":794,"completion":794,"start":3994,"enrollment":3995,"conditions":4396,"interventions":4397},[86],[27],[1869,3984],{"nctId":4074,"briefTitle":4075,"status":103,"phases":4399,"primaryCompletion":4077,"completion":4077,"start":4078,"enrollment":4079,"conditions":4400,"interventions":4401},[86],[27],[1869,4067],{"nctId":3042,"briefTitle":3043,"status":103,"phases":4403,"primaryCompletion":3045,"completion":3045,"start":3046,"enrollment":19,"conditions":4404,"interventions":4405},[86],[15],[1869,581],{"nctId":4407,"briefTitle":4408,"status":103,"phases":4409,"primaryCompletion":4410,"completion":4410,"start":4411,"enrollment":4412,"conditions":4413,"interventions":4414},"NCT04594252","Copper Balance in Healthy Participants Administered ALXN1840",[86],"2020-11-18","2020-07-01",17,[15],[1869],{"nctId":4416,"briefTitle":4417,"status":103,"phases":4418,"primaryCompletion":4419,"completion":4419,"start":4420,"enrollment":1394,"conditions":4421,"interventions":4422},"NCT05303324","Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults",[86],"2019-10-09","2019-07-04",[15],[1869],{"nctId":4424,"briefTitle":4425,"status":103,"phases":4426,"primaryCompletion":3005,"completion":4427,"start":4428,"enrollment":1394,"conditions":4429,"interventions":4430},"NCT04610580","Bioavailability Study of 2 Oral Formulations of ALXN1840",[86],"2021-04-26","2021-01-31",[15],[1869],{"nctId":4432,"briefTitle":4433,"status":103,"phases":4434,"primaryCompletion":4435,"completion":4435,"start":4436,"enrollment":12,"conditions":4437,"interventions":4438},"NCT05641311","Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants",[86],"2019-05-02","2019-02-20",[27],[1869],{"trials":4440,"activeCount":97},[4441,4450],{"nctId":4442,"briefTitle":4443,"status":103,"phases":4444,"primaryCompletion":4445,"completion":4446,"start":4447,"enrollment":1130,"conditions":4448,"interventions":4449},"NCT02273596","Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients",[87],"2016-10-27","2018-11-07","2014-11-24",[27],[1869],{"nctId":4451,"briefTitle":4452,"status":103,"phases":4453,"primaryCompletion":4454,"completion":4454,"start":2647,"enrollment":525,"conditions":4455,"interventions":4456},"NCT04573309","Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840",[87],"2022-06-07",[27],[1869],{"trials":4458,"activeCount":97},[4459,4463],{"nctId":1862,"briefTitle":1863,"status":116,"phases":4460,"primaryCompletion":1865,"completion":1865,"start":1866,"enrollment":414,"conditions":4461,"interventions":4462},[88],[27],[1869,1851],{"nctId":1937,"briefTitle":1938,"status":116,"phases":4464,"primaryCompletion":1940,"completion":1940,"start":312,"enrollment":1941,"conditions":4465,"interventions":4466},[88],[27],[1869,1926],{"trials":4468,"activeCount":97},[],{"trials":4470,"activeCount":97},[4471],{"nctId":4472,"briefTitle":4473,"status":1365,"phases":4474,"conditions":4475,"interventions":4476},"NCT05686564","Early Access Program for ALXN1840 in Patients With Wilson Disease",[],[27],[1869],{"intervention":4478,"totalTrials":611,"cells":4479},"Sebelipase Alfa",{"EARLY_PHASE1":4480,"PHASE1":4482,"PHASE2":4484,"PHASE3":4511,"PHASE4":4532,"NA":4534},{"trials":4481,"activeCount":97},[],{"trials":4483,"activeCount":97},[],{"trials":4485,"activeCount":97},[4486,4494,4502],{"nctId":4487,"briefTitle":4488,"status":103,"phases":4489,"primaryCompletion":4490,"completion":4490,"start":4491,"enrollment":93,"conditions":4492,"interventions":4493},"NCT02112994","Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency",[87],"2017-12-28","2014-06-24",[24],[4478],{"nctId":4495,"briefTitle":4496,"status":116,"phases":4497,"primaryCompletion":4498,"completion":4498,"start":4499,"enrollment":28,"conditions":4500,"interventions":4501},"NCT02193867","Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency",[87],"2018-10-30","2014-06-06",[24],[4478],{"nctId":4503,"briefTitle":4504,"status":103,"phases":4505,"primaryCompletion":874,"completion":874,"start":4506,"enrollment":33,"conditions":4507,"interventions":4509},"NCT01488097","Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency",[87],"2011-12-12",[4508,24,2563],"Cholesterol Ester Storage Disease (CESD)",[4510],"sebelipase alfa",{"trials":4512,"activeCount":97},[4513,4523],{"nctId":4514,"briefTitle":4515,"status":103,"phases":4516,"primaryCompletion":4517,"completion":4517,"start":4518,"enrollment":525,"conditions":4519,"interventions":4521},"NCT01371825","Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency",[87,88],"2018-01-03","2011-05-04",[24,4520],"Wolman Disease",[4522],"Sebelipase alfa",{"nctId":4524,"briefTitle":4525,"status":103,"phases":4526,"primaryCompletion":4527,"completion":4528,"start":4529,"enrollment":4277,"conditions":4530,"interventions":4531},"NCT01757184","Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency",[88],"2014-05-30","2018-12-11","2013-01-22",[24],[4478],{"trials":4533,"activeCount":97},[],{"trials":4535,"activeCount":97},[4536],{"nctId":4537,"briefTitle":4538,"status":1365,"phases":4539,"conditions":4540,"interventions":4541},"NCT02376751","An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency",[],[24],[4510],{"intervention":1667,"totalTrials":405,"cells":4543},{"EARLY_PHASE1":4544,"PHASE1":4546,"PHASE2":4548,"PHASE3":4554,"PHASE4":4556,"NA":4558},{"trials":4545,"activeCount":97},[],{"trials":4547,"activeCount":97},[],{"trials":4549,"activeCount":97},[4550],{"nctId":1654,"briefTitle":1655,"status":103,"phases":4551,"primaryCompletion":1657,"completion":1657,"start":1658,"enrollment":1659,"conditions":4552,"interventions":4553},[86,87],[1661,1662,1663,1664,1665],[1667,1645],{"trials":4555,"activeCount":97},[],{"trials":4557,"activeCount":97},[],{"trials":4559,"activeCount":97},[4560],{"nctId":4561,"briefTitle":4562,"status":1365,"phases":4563,"conditions":4564,"interventions":4567},"NCT04757259","Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib",[],[4565,4566],"Relapsed\u002FRefractory Chronic Lymphocytic Leukemia","Non-hodgkin's Lymphoma",[4568],"cerdulatinib",{"intervention":4570,"totalTrials":428,"cells":4571},"Standard of Care Medications",{"EARLY_PHASE1":4572,"PHASE1":4574,"PHASE2":4576,"PHASE3":4578,"PHASE4":4580,"NA":4582},{"trials":4573,"activeCount":97},[],{"trials":4575,"activeCount":97},[],{"trials":4577,"activeCount":97},[],{"trials":4579,"activeCount":97},[],{"trials":4581,"activeCount":97},[],{"trials":4583,"activeCount":97},[4584],{"nctId":4585,"briefTitle":4586,"status":103,"phases":4587,"primaryCompletion":4588,"completion":4588,"start":4589,"enrollment":3157,"conditions":4590,"interventions":4591},"NCT02763215","The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment",[],"2019-01-21","2016-05-19",[27],[4570],{"intervention":4593,"totalTrials":428,"cells":4594},"Retrospective Case Only",{"EARLY_PHASE1":4595,"PHASE1":4597,"PHASE2":4599,"PHASE3":4601,"PHASE4":4603,"NA":4605},{"trials":4596,"activeCount":97},[],{"trials":4598,"activeCount":97},[],{"trials":4600,"activeCount":97},[],{"trials":4602,"activeCount":97},[],{"trials":4604,"activeCount":97},[],{"trials":4606,"activeCount":97},[4607],{"nctId":4608,"briefTitle":4609,"status":103,"phases":4610,"primaryCompletion":4611,"completion":4611,"start":4612,"enrollment":611,"conditions":4613,"interventions":4615},"NCT02235493","Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09",[],"2014-09","2014-08",[21,4614],"Bone Disease",[4593],{"intervention":4617,"totalTrials":428,"cells":4618},"ACH-126, 443",{"EARLY_PHASE1":4619,"PHASE1":4621,"PHASE2":4623,"PHASE3":4625,"PHASE4":4627,"NA":4629},{"trials":4620,"activeCount":97},[],{"trials":4622,"activeCount":97},[],{"trials":4624,"activeCount":97},[],{"trials":4626,"activeCount":97},[],{"trials":4628,"activeCount":97},[],{"trials":4630,"activeCount":97},[4631],{"nctId":4632,"briefTitle":4633,"status":116,"phases":4634,"completion":2670,"enrollment":2103,"conditions":4635,"interventions":4636},"NCT00037622","Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.",[90],[2846],[4617]]